Antiepileptic drugs’ tolerability and safety : a systematic review and meta-analysis of adverse effects in dogs by Charalambous, Marios et al.
RESEARCH ARTICLE Open Access
Antiepileptic drugs’ tolerability and safety –
a systematic review and meta-analysis of
adverse effects in dogs
Marios Charalambous1*, Sara K. Shivapour2, David C. Brodbelt3 and Holger A. Volk4
Abstract
Background: The safety profile of anti-epileptic drugs (AEDs) is an important consideration for the regulatory
bodies, owners and prescribing clinicians. Information on their adverse effects still remains limited. A systematic
review including a meta-analytic approach was designed to evaluate existing evidence for the safety profile of AEDs
in canine patients. Electronic searches of PubMed, CAB Direct and Google scholar were carried out without date or
language restrictions. Conference proceedings were also searched. Peer-reviewed full-length studies reporting
adverse effects of AEDs in epileptic and healthy non-epileptic dogs were included. Studies were allocated to three
groups based on their design. Individual studies were evaluated based on the quality of evidence (study design,
study group sizes, subject enrolment quality and overall risk of bias) and the outcome measures reported
(proportion of specific adverse effects for each AED, prevalence and 95 % confidence interval of the affected
population in each study and comparative odds ratio of adverse effects for AEDs).
Results: Ninety studies, including six conference proceedings, reporting clinical outcomes of AEDs’ adverse effects
were identified. Few studies were designed as blinded randomised controlled clinical trials. Many studies included
low canine populations with unclear criteria of subject enrolment and short treatment periods. Direct comparisons
suggested that imepitoin and levetiracetam might have a better safety profile than phenobarbital, whilst the latter
might have a better safety profile than potassium bromide. However, none of these comparisons showed a
statistically significant difference. Comparisons between other AEDs were not possible as a considerable amount of
studies lacked power calculations or adequate data to allow further statistical analysis. Individual AED assessments
indicated that levetiracetam might be one of the safest AEDs, followed by imepitoin and then phenobarbital and
potassium bromide; these findings were all supported by a strong level of evidence. The safety profile in other
AEDs was variable, but weak evidence was found to permit firm conclusions or to compare their safety to other
AEDs.
Conclusions: This systematic review provides objective evaluation of the most commonly used AEDs’ adverse
effects. Adverse effects usually appeared mild in all AEDs and subsided once doses and/or serum levels were
monitored or after the AED was withdrawn. Although phenobarbital might be less safe than imepitoin and
levetiracetam, there was insufficient evidence to classify it as an AED with a high risk of major adverse effects. It is
important for clinicians to evaluate both AEDs’ effectiveness and safety on an individual basis before the selection
of the appropriate monotherapy or adjunctive AED therapy.
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Background
In human medicine, a plethora of new antiepileptic
drugs (AEDs) have been developed over the years for
use either as monotherapy or adjunctive therapy [1].
Many of these drugs are now also used in veterinary
medicine. This has led to an increase in the arsenal of
AEDs used to treat canine epilepsy. As a rule, AEDs are
evaluated on the grounds of their effectiveness and
safety through clinical trials and experimental laboratory
studies before they are approved for use in patients by
the regulatory authorities, e.g. the European Medicines
Agency (EMA) or the US Food and Drug Administration
(FDA) [2]. The safety profile of drugs is an important
consideration for their approval by the authorities and
use by prescribing clinicians on their clients’ animals [2, 3].
It affects clinicians’ decisions to prescribe specific
AED(s), as serious adverse effects can lead to chronic
complications or even death. Less serious, but none-
theless important, adverse effects can significantly im-
pact quality of life, leading to systematic illness which
may increase the overall cost of treatment [3, 4].
Ultimately, the benefits of an effective AED may be
outweighed by its adverse effects, and the latter should
be always taken into consideration.
Many potential adverse effects for AEDs have been re-
ported, but the evidence behind the severity of these ef-
fects or the likelihood of their occurrence has not been
systematically compiled [5, 6]. Randomised clinical trials
(RCTs) are a considerable source of evidence for some
common or expected adverse effects [4]. However, infor-
mation about serious, rare, and/or long-term adverse
effects can typically be found in studies such as case
reports, case series and observational studies [7, 8].
Consequently, the clinician will need to search for infor-
mation from sources other than RCTs [7, 8]. Identifica-
tion of all relevant studies can be time-consuming and
for a busy practitioner it may be more effective to review
this information via a systematic review. Systematic re-
views are one of the most powerful and reliable tools to
assess the severity and the probability of occurrence of
AEDs’ adverse effects across the spectrum of primary
literature [9–12].
Although evidence for AEDs’ efficacy has been re-
cently reported and evaluated in a systematic review
[13], it has been suggested that, apart from the efficacy,
the selection of the appropriate AED should be also
largely influenced by its safety profile [14]. To our know-
ledge there is only one systematic review in the field of
canine epilepsy which evaluated the safety profile of a
single AED, potassium bromide, across species and aeti-
ology of seizures [15]. However, a systematic review of
the adverse effects observed during treatment with any
AED(s) in dogs, as well as AEDs’ safety profile compari-
sons, has not been reported. The aim of this systematic
review was to perform an objective analysis of AEDs’ ad-
verse effects in dogs, in order to provide evidence-based
information on AEDs’ safety profiles.
Methods
Search strategy
The literature search aimed to identify all studies asses-
sing or reporting the adverse effects of an AED in dogs.
Specifically, studies were evaluated based on the inclu-
sion criteria below:
 Criterion 1-Type of study: Peer-reviewed studies in
English (or translated). Experimental laboratory ani-
mal studies, clinical trials, observational and descrip-
tive studies were included.
 Criterion 2-Case definition: For the clinical studies,
dogs with IE were included as previously defined
[13]. Briefly this required dogs within a certain age
range, unremarkable interictal neurological status
and diagnostic investigation for seizures. For the ex-
perimental laboratory animal studies (ELAS), healthy
non-epileptic dogs were also included; for the latter
a clear diagnostic investigation or health statement
should have been reported in the study to exclude
the possibility of underlying diseases.
 Criterion 3-Treatment: Dogs treated with any AED
available used in canine IE were included. Doses and
serum concentrations of AEDs, frequency of drug
administration and treatment period were consid-
ered important information to record. Dogs treated
with methods other than pharmacological interven-
tion, e.g. homoeopathy methods, surgery, food trials,
nerve stimulation, were excluded.
 Criterion 4-Outcome: Studies had to assess or report
adverse effects following administration of AED(s) in
canine subjects. Studies were conducted either to
specifically assess or report AED(s)’ safety (primary
evidence studies) or to assess an outcome other than
AED(s)’ safety (i.e. efficacy), while also reporting ad-
verse effects (supportive evidence studies). Assess-
ment of the adverse effects should have been
performed by the investigators or owner.
Search strategies included use of electronic search en-
gines for publication databases, searching of reference
lists of published papers and proceedings of relevant sci-
entific conferences. Electronic databases used were Pub
Med (www.ncbi.nlm.nih.gov/PubMed), CAB Abstracts
(www.cabdirect.org) and Google Scholar (www.scholar.-
google.com). Final electronic searches were carried out
on 30 February 2015 by the primary and the second
author independently, with no date or language res-
trictions. The search terms used in both search engines
were as follows: (dog OR dogs OR canine) AND
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[(phenobarbital OR phenobarbitone OR primidone OR
PBr OR KBr OR potassium bromide OR bromide OR
nimodipine OR zonisamide OR ELB138 OR imepitoin
OR levetiracetam OR verapamil OR gabapentin OR gaba
OR topiramate OR felbamate OR pregabalin) OR [(treat-
ment OR management) AND (epilepsy OR seizures)]
OR (anti-convulsant OR anti-seizuring OR anti-epileptic
OR AED) AND (safety OR safe OR adverse-effect OR
adverse-effect OR effect OR undesirable effect OR toler-
ability OR toxicity OR drug toxicity OR reactions OR
disease). Hand searching for articles from the reference
lists of publications and searching major veterinary
neurology conference meeting proceedings from 1970 to
2015 and relative textbook chapters was carried out by
the primary and second authors independently. Confer-
ence proceedings were searched for the Annual Con-
gresses of the European Society and College of
Veterinary Neurology (ESVN ⁄ ECVN) and the American
College of Veterinary Internal Medicine (ACVIM).
Other conference proceedings were searched only if the
reference list of identified publications indicated this. All
items returned by the search engines, hand searches and
correspondence were recorded and entered into the
screening process.
Study selection
Restrictions based on publication date or language were
not imposed. Studies written in non-English language
were assessed initially based on an English translation
(Google Translate software) and then verified by a veter-
inarian fluent in the language of publication.
A two-stage screening process was used [13] and the
process was performed by the primary author. Firstly,
studies of relevance to the systematic review objectives
were identified (stage 1) and, secondly, studies likely to
provide evidence of the highest available quality and suf-
ficient detail for assessing the outcome measures and
methodology were selected (stage 2). Stage 1 of the
screening process identified from the total search results
any studies that: (a) fulfilled inclusion criterion 1 and (b)
reported findings related to the adverse effects and safety
of AEDs administered in dogs. Stage 1 assessment evalu-
ated the retrieved papers’ titles and abstracts only. At
stage 2, papers were selected for full data extraction ac-
cording to the inclusion criteria 2, 3 and 4 and were
evaluated in detail on the grounds of the quality of evi-
dence and outcomes by MC.
Assessment of quality of evidence
Blinded RCTs (bRCTs) and blinded randomised ELAS
(bRELAS) were considered most likely to produce higher
quality evidence, followed by non-blinded RCTs
(nbRCTs) and non-blinded randomised ELAS (nbRE-
LAS), then non-randomised clinical trials (NRCTs) and
non-randomised ELAS (NRELAS), uncontrolled clinical
trials (UCTs) and uncontrolled ELAS (UELAS), cohort,
case–control and cross sectional studies and lastly case
series and reports [16–18]. Accordingly, the studies were
allocated based on their design to one of three groups,
i.e. bRCTs, bRELAS, nbRCTs and nbRELAS (first group),
NRCTs, NRELAS, UCTs, UELAS, cohort, case–control
and cross-sectional studies (second group) and case series
and reports (third group).
As a general rule, the studies in the first group (bRCTs
and bELAS in particular) were considered to provide
higher quality evidence, followed by the studies in the
second and third group. In addition, a three-part system
of evidence quality assessment to indicate the strengths
and weaknesses of each study within each group was
used [13, 19]: (a) study group sizes, (b) subject enrol-
ment quality and (c) overall risk of bias based on
Cochrane [20] and Syrcle’s [21] ‘risk of bias’ assessment
tool in order to provide an indicator of confidence asso-
ciated with the findings of each study. For instance,
bRCTs or bRELAS with large group sizes, clear inclusion
criteria, thorough diagnostic investigations and low over-
all risk of bias were considered to provide the highest
available quality of evidence.
Study group sizes
This characteristic was categorized for each study using
the following system [13, 19]: (a) >50 subjects per group
(‘good’ number of subjects), (b) 20–50 subjects per
group (‘moderate’ number), (c) 10–19 subjects per group
(‘small’ number) and (d) <10 subjects per group (‘very
small’ number).
Assessment of subject enrolment quality
Data on investigations to reach the diagnosis of IE were
retrieved to evaluate the quality of subject enrolment in
each study as ‘well characterized’, ‘fairly characterized’,
‘poorly characterized’ or ‘unclear.’ Well characterized
diagnoses were defined as diagnostic investigations that
included clinical signs and thorough test results consist-
ent with the diagnosis of IE; specifically, the signalment,
the absence of neurological deficits between the ictal
phases, unremarkable routine biochemical and haemato-
logical blood tests and imaging results (including brain
MRI and/or CT) and/or normal cerebrospinal fluid
(CSF) analysis for all cases of the study. Fairly character-
ized, used for intermediate situations, were defined as
diagnostic investigations that were based on signalment,
clinical examination and basic diagnostic investigation
(i.e. blood tests only), with only some study cases having
had advanced brain imaging and/or CSF analysis. Poorly
characterized were defined as diagnostic investigations
that were based on signalment, clinical examination
and/or basic diagnostic investigation (i.e. blood tests)
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only. Unclear related to reports where the approach to
diagnosis of IE was not clearly stated (e.g. when clinical
signs were not stated and insufficient or no details of
diagnostic tests were provided or when dogs with IE
were included without reporting details on diagnostic
investigation).
For the ELAS, which included non-epileptic healthy
animals, ‘clearly characterized’ were the studies that de-
fined diagnostic investigations and thorough test results
to exclude any systemic illness; ‘unclear’ were character-
ized when diagnostic investigations to rule out diseases
were not clearly stated or when dogs were included and
considered healthy without reporting details on diagnos-
tic procedures.
Assessment of overall risk of bias
The overall risk of bias in the clinical trials was assessed
based on the criteria of the Cochrane ‘risk of bias’ as-
sessment tool [20]. Syrcle’s ‘risk of bias’ assessment tool
[21] was used to assess the overall risk of bias in ELAS.
The latter tool is an adapted version of the Cochrane
one and was designed to facilitate critical appraisal of
evidence from ELAS.
Each of the following study components was catego-
rized as presenting a ‘high’, ‘low’ or ‘unclear’ risk of
introducing bias to the study findings: random sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
completeness of outcome data, selective reporting of
outcomes and other sources of bias. For ELAS, two fur-
ther components-random housing and baseline charac-
teristics of dogs - were also assessed and mentioned as
part of the “other sources of bias” section. Case series
and reports as well as observational studies were consid-
ered to be of high overall risk of bias.
Level of the studies’ evidence
The level of evidence provided for the safety profile of
each AED was based on the overall quality of evidence
of the studies. The level of evidence was allocated ac-
cording to a previous similar system [13, 19] which was
extensively modified for the needs of the current study:
‘strong’ evidence was provided for the safety profile
when at least one bRCT and/or bRELAS reported or
assessed the adverse effects of an AED; ‘weak’ evidence
was provided for the safety profile when bRCTs and/or
bRELAS were not available.
Assessment of outcome measures
The outcome measure of this study was the evaluation
of the safety profile of AED(s) administered in dogs. The
adverse effects were organized by body system (e.g.
neurological, gastro-intestinal, dermatological, etc.) and
types, including type I (dose dependent and predictable)
and type II (idiosyncratic-dose independent and unpre-
dictable). Different terms used by the studies but de-
scribing the same adverse effects (e.g. drowsiness and
somnolence, wobbly gait and ataxia, lethargy and sed-
ation, etc.) were considered synonymous and only one
term was selected for use in the analysis. The outcome
measure was assessed according to the methods below:
Proportion of specific adverse effects for each AED
This was expressed as a percentage and calculated for
each AED by dividing the number of studies that re-
ported a specific adverse effect by the total number of
the studies for this AED. If an AED was used as a mono-
therapy and adjunctive therapy, further calculations were
also performed for each sub-category.
Prevalence and 95 % confidence interval of the affected
population in each study
Prevalence was expressed as a percentage and calculated
for each study by dividing the number of subjects that
developed adverse effects during the specified study
period by the total size of the study population. The
95 % confidence interval (95 % CI) of the proportion of
study animals that developed adverse effects related to
the AED(s) was calculated by standard methods [22].
This was used as a further indicator of an AED’s safety
profile. If the 95 % CI of affected dogs (based on 95 %
CI calculations) were ≥ 50 %, then it was considered that
the majority of the study population experienced adverse
effects.
For each study, the period of treatment, AED’s doses
and serum levels were reported with the aim to evaluate
the association of these values with the prevalence of
each AED’s adverse effects.
Statistical analysis
For the comparison groups’ studies, a further approach
was conducted to identify statistical differences between
studies with regards to reported adverse effects. For each
AED study, the total number of patients experiencing
adverse effects and/or the number of patients experien-
cing specific adverse effects (e.g. sedation, ataxia, poly-
uria, etc.) in all therapeutic groups were retrieved. The
odds ratio (OR) was then estimated in order to indicate
the increased or decreased odds of observing a specific
adverse effect(s) in total for an AED compared to its
control group (comparison AED or placebo or untreated
animals). Statistical analysis was undertaken following
the guidelines of the Handbook of the Cochrane Collab-
oration 5.0. The OR for dichotomous data was calcu-
lated using the random-effects model in Review
Manager 5.3. Heterogeneity between studies was calcu-
lated using the Chi square test and was considered to be
heterogeneous when P ≤ 0.1. I2 values of no more than
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25, 26 to 74 % and no less than 75 % were considered as
“low”, “moderate” and “high” heterogeneity, respectively.
Associations were considered to be statistically signifi-
cant at P < 0.05. P values between 0.05 and 0.1 were con-
sidered as statistical trends of potential interest.
Results
Description of studies
By 29 December 2015, the search strategy had identified
a total of 368 unique citations; 347 from the electronic
searches of PubMed, CAB Abstracts, Google Scholar
and manual searches from the publications’ reference
lists, 16 from manual searching of major conference pro-
ceedings and 6 unpublished studies included as part of
published data. Two hundred ninety two items fulfilled
stage 1 screening criteria. Of these, 90 final studies (pub-
lished between 1981 and 2015) also fulfilled stage 2
selection criteria and were thus selected for review.
The vast majority of studies were allocated in the sec-
ond (i.e. non-blinded, non-randomised and uncontrolled
studies) and third (i.e. retrospective case series and
reports) group. A few studies included more than one
sub-study (i.e. a clinical trial and/or ELAS and/or retro-
spective case series part); accordingly, such studies were
included in more than one group. Therefore, study
designs represented were five bRCT [23–27], two
nbRCT [28, 29] and seven nbRELAS [25, 30–35] in the
first group, six NRCTs [36–41], 11 NRELAS [42–52], 22
UCTs [44, 48, 53–71], six UELAS [34, 72–76] and one
cross sectional study [3] in second group, and 19
retrospective case series [77–95] and 16 case reports
[96–111] in the third group. In addition, five unpub-
lished studies described adverse effects and were re-
ported briefly in EMA report; thus all these were
considered as one study [112] and were not included in
any category as there was insufficient information as far
as their design was concerned.
Overall, the 90 selected studies reported 12 AEDs. In
all studies but one [43], the AEDs were orally adminis-
tered. Within each study, one or more AEDs were evalu-
ated as a monotherapy and/or adjunct to other AEDs.
Disease characterisation
In the majority of the studies, the inclusion criteria for
diagnosing IE were not well characterized. According to
the described grading system for subject enrolment qual-
ity, 16 studies [27, 33, 53, 61, 63, 64, 68, 80, 81, 90, 96,
97, 100, 101, 110, 111] enroled treatment groups of well
characterized IE, 13 studies [3, 44, 48, 54–57, 62, 66, 67,
77–79] enroled treatment groups of fairly characterized
IE, and 14 studies [23–26, 39, 58, 59, 65, 74, 82, 84, 88,
108, 109] enroled treatment groups of poorly character-
ized IE. In 26 studies [28, 29, 36–38, 50, 60, 69, 70, 75,
83, 85–87, 89, 91–94, 98, 99, 102–106], the diagnostic
procedures for enrolment of cases with IE were unclear.
As far as the ELAS including healthy animals were
concerned, eight [31, 36, 45, 46, 50–52, 73] enroled
treatment groups of clear and 14 [25, 30, 32, 34, 35, 37,
38, 42, 43, 47, 49, 72, 76] enroled treatment groups of
unclear or unknown diagnostic investigation for ruling
out other diseases. In one report, a dog was non-
epileptic and was treated with phenobarbital and chlo-
mipramine due to anxiety and aggression, but the diag-
nostic investigation for this was unclear [107].
Study group sizes
The vast majority of studies reported the total number
of dogs evaluated. The majority of studies evaluated
small or very small study size groups. Thirteen studies
[25, 26, 40, 50, 62, 69–71, 75, 82, 88, 90, 113] evaluated
groups with a good number of dogs, 13 studies [23, 24,
32, 37, 39, 65, 74, 77, 79, 80, 91, 94, 95] evaluated groups
with a moderate number of dogs, 26 studies [3, 28, 34,
36, 38, 44–46, 48, 53, 54, 56–61, 63, 64, 66, 70, 75, 81,
83, 84, 114] evaluated groups with a small number of
dogs and 38 studies [33–35, 39, 42, 43, 51–53, 55, 67,
68, 72, 73, 76, 78, 85, 87, 89, 92, 93, 96–100, 102–111,
115, 116] evaluated groups with a very small number of
dogs. In two studies, the study group size was unclear
[47, 49].
Signalment and baseline characteristics of study subjects
Baseline characteristics (such as breed, age and sex) of
total enroled dogs were reported to some extent for all
90 studies. Clear presentation of statistical comparison
of intervention groups with respect to signalment and
baseline disease characteristics was not commonly
encountered.
In all studies reporting baseline data, the recruited
dogs represented multiple breeds, both sexes and a wide
range of ages at study entry (median 5, mean 4, range
0.5-7 years). Major affected breeds were crossed-breeds
and pure breeds such as Labrador and Golden Retrievers
followed by German Shepherd dogs, Beagles, Boxers and
Poodles. In the majority of the studies more males were
affected compared to females, though these differences
were not evaluated statistically.
Methodological quality of included studies
The vast majority of studies revealed high and/or un-
clear risk of bias for all the components (Fig. 1). As
stated in the methods, retrospective case series and re-
ports were not included in the methodological quality
assessment as these were considered to be at an overall
high risk of bias.
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Randomization and allocation concealment
Studies in group A used randomization to allocate the
dogs and were considered to provide a low risk of bias.
Eight studies [25, 28, 29, 32–35, 68] did not offer enough
detail to confirm that allocation concealment was per-
formed. Five studies stated that randomization was
concealed without further details. Two studies [23, 27]
assigned by random blocking (random allocation to
blocks of 10 and 6 respectively). One study [27] used
pre-defined randomization lists under double-blinded
conditions. One study [31] used drawing lots and two
studies [24, 30] used a computer-generated list of
random numbers.
Blinding of outcome assessment
Only in five studies [23–27], in group A, blinding was
clearly described; these were also considered to be at
low risk. In these five studies, blinding was applied to
all participants, personnel and outcome assessment.
In one of them [23] all but the primary investigator
were blinded.
Incomplete outcome data
Ten studies presented outcome data from all enroled
dogs in the treatment group to which they were origin-
ally allocated and there were no losses between enrol-
ment and evaluation [30, 33, 42, 51, 53, 59, 61, 67, 73,
78]. The same studies were considered to be at low risk
of bias. In two studies, it was unclear whether all dogs
completed the study, as inadequate information was pro-
vided [60, 64]. Across the remaining studies, there were
dogs that were euthanized or excluded due to poor seiz-
ure control, owner request or for unidentified reasons;
thus there were losses between the initial study popula-
tions and the final number of the dogs.
Selective reporting
It was difficult to assess selective reporting as study pro-
tocols were not sought beyond the information pub-
lished. In two reports [29, 112] further information was
attempted to be retrieved but complete protocols were
never obtained.
Acknowledgment of other sources of bias
Twelve studies reported financial support [24, 26–28, 41,
44, 53, 58, 61, 68, 73, 79] but there was not adequate
evidence to support whether this biased the results. One
study [54] clearly mentioned that there was no financial
support, while the remaining studies failed to report fi-
nancial support.
In two studies [28, 78] the statistical analysis was not
clarified. In one study [25], many dogs were excluded
from both groups mainly for treatment-related reasons
(post-randomisation bias). Six studies [29, 49, 60, 64, 70,
86] were conference abstracts, thus no further informa-
tion could be retrieved. One dog in one study [66] and
two dogs in two studies [28, 63] were diagnosed with
symptomatic epilepsy (i.e. a cause was identified); this
could potentially affect the final results on AED safety
profile. Conflict of interest was clearly stated in one
study [25].
In the ELAS, specifically, nine studies [25, 30, 33, 34,
42, 44, 51, 52, 68] reported details for the experimental
dogs’ housing. Random housing of the dogs occurred in
all but nine studies [34, 35, 37, 42–44, 49, 72, 73]. The
baseline characteristics of the dogs were reported in nine
studies [25, 30, 33, 42, 44, 51, 52, 68, 73] and were
similar for all the experimental groups in seven studies
[25, 30, 33, 42, 44, 51, 52].
AEDs safety profile
A) Safety profile for each AED individually
Proportions of adverse effects for each AED are summa-
rized in the text and presented in Figs. 2, 3, 4, 5, 6, 7, 8,
9, 10, 11. Details of doses and serum concentrations of
AED(s), period of treatment as well as prevalence of ad-
verse effects and 95 % CI of the proportion of affected
cases (included type and most frequently occurred) for
each study are summarized in the text and provided in
detail in Tables 1, 2, 3, 4, 5, 6, 7.
Fig. 1 Risk of bias. Risk of bias assessment presented as percentages across all included studies
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Phenobarbital
There was an overall strong level of evidence provided
for the phenobarbital safety profile. Forty-three studies
[3, 23, 25, 27–29, 31, 33, 36–40, 42, 43, 45, 46, 49, 50,
52, 53, 60, 69, 71, 74–76, 79–81, 83–85, 87, 93–95, 98,
100, 103, 107, 109, 111] presented data about the safety
profile of phenobarbital as a monotherapy agent, giving
a combined sample size of 1003 dogs.
Twenty-seven studies reported type I adverse effects
(dose dependent/predictable), including neurological
signs and clinical pathological findings as the most com-
mon (Table 1). Specifically, these adverse effects most
Fig. 2 Proportion of specific type I adverse effects for phenobarbital. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for phenobarbital monotherapy
Fig. 3 Proportion of specific type II adverse effects for phenobarbital. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for phenobarbital monotherapy
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commonly included increased serum ALP activity and
ALT activity followed by sedation, ataxia, polydipsia,
polyuria, polyphagia, euthyroid sick syndrome, hyper-
activity, increased serum γ-GT activity, decreased serum
albumin and diarrhoea. Less commonly, vomiting, prur-
itus, chronic clinical hepatopathy/toxicity, increased
serum GLDH activity, AST activity, cholesterol, bile
acids and bilirubin activity, aggression, anorexia and de-
creased serum total proteins were reported (Fig. 2).
Twenty studies reported alterations in one or multiple
liver enzymes, but only three of them reported chronic
clinical hepatopathy/toxicity. The occurrence of euthyr-
oid sick syndrome and asymptomatic/subclinical pan-
creatitis may have been underestimated because only a
very few studies included the relevant diagnostic tests to
evaluate these disorders. Two studies [31, 33] evaluated
the effect of phenobarbital on adrenal function and
found no significant effect. The same studies reported
no adverse effects, although they focused on reporting
adverse effects related to adrenal function. One study
[71] reported that adrenal function might have been af-
fected by phenobarbital (i.e. altered ACTH stimulation
and dexamethasone suppression tests despite normal en-
dogenous ACTH concentrations).
Fifteen studies reported type II adverse effects (idio-
syncratic/unpredictable) with hematological signs as the
most common (Table 1). Specifically, the most com-
monly reported adverse effects included blood dyscrasias
(i.e. anemia, thrombocytopenia, leucopenia and/or pan-
cytopenia) followed by pancreatitis, superficial necrolytic
dermatitis and lastly dyskinesia (i.e. twitching episodes)
(Fig. 3). In one study [50] elevated serum canine
Fig. 4 Proportion of type I adverse effects for imepitoin. Each adverse effect represents the percentage of studies that reported this specific
adverse effect for imepitoin monotherapy
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pancreatic lipase immunoreactivity (cPLI) concentration
was detected in some dogs, but further diagnostic tests
and clinical evaluation was not performed; thus, it is un-
known if the dogs had developed clinical pancreatitis. In
addition, in one study [81], 212 dogs with IE treated
with phenobarbital monotherapy or combined therapy
were evaluated and only 9 were found to have
phenobarbital-induced blood dyscrasias, giving a preva-
lence of 4.2 % (95 % CI: 1.5–7.0 %).
Adequate data to allow calculations of the preva-
lence of adverse effects was reported in 25/43 (58 %)
of the studies (Table 1). From these, 13/25 (52 %)
showed >50 % prevalence of at least one adverse
effect for the specific period of treatment they were
conducted. Based on the 95 % CI, the majority of the
study populations experienced at least one adverse
effect in 11/25 (44 %) studies (Table 1).
Adequate information about the treatment period was
reported in 34/43 (79 %) (Table 1). From these, in 10/34
(29 %) the treatment period was relatively short
(<6 months). Adequate information about the dose was
provided in 28/43 (65 %) studies (Table 1). From these,
19/28 (68 %) and 9/28 (32 %) reported type I and type II
adverse effects respectively. The maintenance doses were
Fig. 5 Proportion of specific type I adverse effects for potassium bromide. Each adverse effect represents the percentage of studies that reported
this specific adverse effect for potassium bromide monotherapy and adjunctive therapy
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higher than the recommended dose range in type I ad-
verse effects (11/19, 58 %), while within normal ranges
for type II adverse effects (7/9, 78 %). Adequate informa-
tion about the phenobarbital serum levels was reported
in 24/43 (56 %) studies (Table 1). From these 17/24
(71 %) and 4/24 (17 %) reported doses for type I and
type II adverse effects respectively. The phenobarbital
serum levels were higher than the recommended thera-
peutic ranges in type I adverse effects (9/17, 53 %), while
within normal ranges for type II adverse effects (4/4,
100 %).
Imepitoin
There was an overall strong level of evidence provided
for the imepitoin safety profile. Six studies [25, 26, 44,
48, 112, 113] presented data about the safety profile of
oral imepitoin either as monotherapy (all studies) and/or
an adjunct to other AEDs (two studies) [44, 48], giving a
combined sample size of 458 dogs. Two studies [25, 44]
included both a clinical trial and ELAS part. EMA ime-
pitoin assessment report [112] included two unpublished
GLP toxicity studies and three unpublished clinical trials
[117–119]; the latter three studies were not clearly dis-
tinguished in the EMA report and thus they were con-
sidered as one study.
Nine studies reported type I adverse effects including
neurological and gastro-intestinal signs as the most
common (Table 2). Specifically, the most common
adverse events included ataxia and polyphagia, followed
by sedation, hyperactivity, increased serum creatinine
activity, vomiting and diarrhoea, disorientation and po-
lydipsia. Less commonly, polyuria, anxiety, tachypnea,
Fig. 6 Proportion of specific type II adverse effects for potassium bromide. Each adverse effect represents the percentage of studies that reported
this specific adverse effect for potassium bromide monotherapy and/or adjunctive therapy
Fig. 7 Proportion of specific type I adverse effects for levetiracetam. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for levetiracetam monotherapy and/or adjunctive therapy
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hypersalivation, decrease in sight and motor activity,
prolapsed nictitating membrane and increased sensitivity
to sound were reported (Fig. 4).
It is worth mentioning that the two GLP toxicity stud-
ies [112] and the ELAS part of one study [25] reported a
few further adverse effects. However, these specific ad-
verse effects were not included in the assessment above
(see Table 2 for details) because higher than therapeutic
doses were administered (3X, 5X or higher the recom-
mended dose) which intended to evaluate the potential
toxicity and tolerability of the drug. The same studies
showed no adverse effects when imepitoin was adminis-
tered in the recommended doses (≤30 mg/kg) apart from
vomiting, hypersalivation and prolapsed nictitating
membrane (as described above).
Adequate data to allow calculations of the prevalence
of adverse effects was reported in 5/9 (55 %) of the studies
(Table 2). From these, only two studies showed >50 %
prevalence of adverse effects for the specific treatment
periods within which they were conducted. However, one
of the studies included a group of dogs receiving imepitoin
adjunctive therapy to phenobarbital or primidone and
therefore the prevalence may have been overestimated in
these. Based on the 95 % CIs, the majority of the
combined study populations experienced adverse effects
in only one study (Table 2).
Fig. 8 Proportion of specific type I adverse effects for zonisamide. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for zonisamide monotherapy and adjunctive therapy
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Adequate information about the treatment period was
reported in 7/9 (78 %) (Table 2). From these, in 6/7
(86 %) the treatment period was relatively short
(<6 months). Adequate information about the doses was
provided in all studies (Table 2). The imepitoin mainten-
ance doses were mainly at the higher recommended
dose, but the toxicology studies in which higher than
recommended doses were used. Adequate information
about the imepitoin serum levels was reported in 2/9
(22 %) studies (Table 2), but no correlation was detected
between imepitoin serum levels and adverse effects.
Potassium bromide
There was an overall strong level of evidence provided
for potassium bromide safety profile as monotherapy
and weak as an adjunctive therapy. Twenty-one studies
[3, 23, 29, 39, 51, 53, 66, 67, 73, 75, 77, 86, 88, 93, 96,
101, 102, 106, 110, 116] presented data about the safety
of potassium bromide either as monotherapy (8 studies)
[3, 23, 29, 39, 50, 51, 73, 86] or adjunctive therapy to
phenobarbital and/or other AEDs (16 studies) [3, 39, 50,
53, 66, 67, 75, 77, 88, 93, 96, 101, 102, 106, 110, 116],
giving a combined sample size of 1940 dogs.
Fifteen studies reported type I adverse effects, includ-
ing neurological signs as the most common (Table 3).
From these, 7/15 (47 %) and 10/15 (67 %) studies re-
ported type I adverse effects for potassium bromide
monotherapy and adjunctive therapy, respectively. Spe-
cifically, in all the studies, the adverse effects most com-
monly reported were ataxia followed by sedation,
polyuria, polydipsia, polyphagia, paraparesis, hyperactiv-
ity, vomiting, increased serum ALP and ALT activity.
Less commonly, diarrhoea, anorexia, aggression and
then tetraparesis, skin issues, euthyroid sick syndrome,
anisocoria, chronic clinical hepatopathy/toxicity, and
lastly increased serum chloride, bile acids and AST
Fig. 9 Proportion of specific type I adverse effects for primidone. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for primidone monotherapy
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activity were reported. A similar pattern was shown in
the adjunctive therapy studies; diarrhoea, skin conditions
and increased amylase and lipase were not reported. In
the monotherapy studies, the most common adverse
effects were ataxia, sedation and hyperactivity followed
by polyuria, polydipsia, polyphagia and diarrhoea; clin-
ical hepatopathy/toxicity, tetraparesis, anisocora, euthyr-
oid sick syndrome, increased serum bile acids and AST
activity were not reported (Fig. 5). In one study [51],
euthyroid sick syndrome was detected in both potassium
bromide-treated and placebo group, indicating that this
AED might not affect thyroid function. In another study
[39], potassium bromide monotherapy did not affect the
thyroxin serum levels.
Nine studies reported type II adverse effects, including
gastro-intestinal signs as the most common (Table 3).
Specifically, pancreatitis was most commonly reported,
followed by panniculitis, generalized appendicular re-
petitive myoclonus, neuromyopathy with generalized
lower motor signs and hyperchloraemia with negative
anion gap (Fig. 6). The latter was detected in a dog, two
days after a loading dose (200 mg/kg BID orally) of po-
tassium bromide was given, but not after regular main-
tenance doses. In one study [50], although clinical
pancreatitis due to potassium bromide or the phenobar-
bital/potassium bromide combination was suspected, it
was not confirmed as the history and clinical status of
the dogs were unknown.
Adequate data to allow calculations of the prevalence
of adverse effects was reported in 14/21 (67 %) of the
studies (Table 3). From these, 7/15 (47 %) showed >50 %
prevalence of adverse effect for the specific period of
treatment they were conducted. Based on the 95 % CI,
the majority of the combined study population experi-
enced at least one adverse effect in 7/15 (47 %) studies
(Table 3).
Adequate information about the treatment period was
reported in 17/21 (81 %) (Table 3). From these, in 5/17
Fig. 10 Proportion of specific type I adverse effects for felbamate. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for felbamate monotherapy and/or adjunctive therapy
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(29 %) the treatment period was relatively short
(<6 months). Adequate information about the doses was
provided in 13/21 (62 %) studies (Table 3). From these
9/13 (69 %) and 4/13 (31 %) reported doses for type I
and type II adverse effects respectively. The maintenance
doses were within the recommended dose margins in all
but one study. Adequate information about the potas-
sium bromide serum levels was reported in 16/21 (76 %)
studies (Table 3). From these, 12/16 (75 %) and 6/16
(37 %) reported serum levels for type I and type II ad-
verse effects respectively. The potassium bromide serum
levels were higher than the recommended margins in
type I adverse effects (7/12, 58 %), while within normal
ranges for type II adverse effects (4/6, 67 %).
Levetiracetam
There was an overall strong level of evidence provided
for the levetiracetam safety profile as monotherapy and
adjunctive therapy. Six studies [24, 27, 53, 60, 72, 90]
presented data about the safety profile of levetiracetam
as monotherapy [27, 72] or adjunct to other AEDs (four
remaining studies), giving a combined sample size of
129 dogs. One study [53] included both a clinical trial
and retrospective case series part.
All the studies reported only type I adverse effects in-
cluding neurological and gastro-intestinal signs as the
most common (Table 4). Specifically, adverse effects
most commonly included were vomiting and sedation
followed by ataxia and hyperactivity. Less commonly, an-
orexia, polyphagia, polydipsia followed by polyuria, diar-
rhoea, aggression, disobedience and attention seeking
were reported (Fig. 7). In the monotherapy study, only
one episode of vomiting occurred. In one study, no ad-
verse effects were reported.
Adequate data to allow calculations of the prevalence
of adverse effects was reported in all studies (Table 4).
From these, only two showed >50 % prevalence of ad-
verse effects for the specific period of treatment during
which it was conducted. Based on the 95 % CI, the ma-
jority of the population experienced adverse effects in
none of the studies (Table 4).
Adequate information about the treatment period was
reported in all of the studies (Table 4). From these, in 3/
7 (43 %) the treatment period was relatively short
(<6 months). Adequate information about the doses was
provided in all of studies (Table 4). The maintenance
doses exceeded the recommended dose range in two
studies. Adequate information about the levetiracetam
serum levels was reported in 2/7 (29 %) studies (Table 4),
Fig. 11 Proportion of specific type I adverse effects for phenytoin. Each adverse effect represents the percentage of studies that reported this
specific adverse effect for phenytoin monotherapy and/or adjunctive therapy
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Table 1 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Studies AED No of dogs
treated
Prevalence 95 % CI
affected cases
Doses of AEDs Serum levels
of AEDs
Treatment
period
Body system affected and adverse
effects
Most common
adverse effects
Adverse
effect type
Boothe et al.
2012
PHB 20 78.5 % 60.5 %–96.5 % mean, 4.11+/−1.1;
range, 3.9–4.9
mg/kg PO BID
mean, 27+/−6;
range, 12.4–36
μg/mL
6 m Neurological (ataxia, hyperactivity,
sedation), GI (vomiting, diarrhea, PP),
PU, PD, ClinPath (increased ALP,
decreased albumin)
ataxia, sedation,
increased serum ALP,
decreased albumin
I
Heynold et al.
1997
PHB 37 35 % 19.6 %–50.4 % mean, 2.5 mg/kg
PO BID
range, 15–40
μg/ml
mean, 50;
range,
8–108 m
Neurological (ataxia, sedation,
aggression), GI (PP), Dermatological
(itching)
sedation I
Löscher et al.
2013
PHB 8 NA NA range, 10–40
mg/kg PO SID
14.7 μg/ml 2.5 m Neurological (sedation, ataxia),
PU, PD
sedation, ataxia,
PU, PD
I
Gaskill et al.
2000
PHB 22 32 % 12.5 %–51.5 % At 3 w: mean,
3.6+/−1.3; range,
1.3–6.0 mg/kg
At 6 m: mean,
3.7+/−1.4; range,
1.3–8.3 mg/kg
At 12 m: mean,
3.7+/−1.6; range,
1.3–8.3 mg/kg
PO SID
At 3 w: mean,
58.6+/−15.0;
range, 33–85
mmol/L
At 6 m:
62.5+/−25.7;
range, 8–120
mmol/L.
At 12 m: mean,
62.2+/−23.51;
range, 11–116
mmol/L
12 m Endocrine (decreased total T4 levels,
increased TSH levels, normal TSH
stimulation test)
euthyroid sick
syndrome
I
Steinberg
2004
PHB
(monotherapy
prior to the
addition of
other AEDs)
14 26.6 % 4.8 %–52.1 % NA PHB: mean,
32.1+/−14.4
μg/ml.
median, 17;
range,
3.3–58.5 m
GI (chronic hepatotoxicity) chronic
hepatotoxicity
I
von Klopmann
et al. 2006
PHB 34 68 % 52.3 %–83.7 % NA NA NA Endocrine (decreased total T4 levels,
normal TSH levels, normal TSH
stimulation test)
euthyroid sick
syndrome
I
Chang et al.
2006
PHB 11 92.5 % 76.9 %–108.1 % NA NA median, 18;
range,
3–72 m
Neurological (ataxia, hyperactivity,
sedation), GI (vomiting, diarrhea, PP),
Dermatological (itching), PU, PD
PD, PU, PP, sedation,
hyperactivity
I
Tipold et al.
2014
PHB 110 57.3 % 48.1 %–66.5 % range, 2–6
mg/kg PO BID
<45 μg/mL 5 m Neurological (sedation), GI
(PP, diarrhea), PU, PD, ClinPath
(increased ALP, γ-GT, ALT and GLDH)
sedation, PP, PU, PD I
Fredso et al.
2015
PHB 6 93 % 70 %–114 % median, 2.7;
mean, 3; range
2.2–3 mg/kg
PO BID
median, 77;
mean, 77.3;
range 55–111
μmol/L
2–12 m Neurological (sedation, ataxia,
hyperactivity, disobedience), GI (PP),
PU, PD
PD, PP I
Schwartz-
Porsche et al.
1985
PHB 15 93 % 80.1 %–105.9 % range, 5–17
mg/kg PO SID
range,
19–57 μg/ml
mean, 15;
range,
7.3–32 m
Neurological (sedation, ataxia), GI
(PP), PD, ClinPath (ALT, ALP, GLDH)
ataxia, sedation,
PP, PD
I
Gaskill et al.
2005
PHB 12 NA NA median, 5; range,
2.1–12.9 mg/kg
PO SID
mean, 22.8;
range, 9.7–44.2
μg/ml
median, 20.4;
range, 4–78 m
ClinPath (increased ALT, ALP) increased ALT, ALP I
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Table 1 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Farnbach et al.
1984
PHB 42 2.4 % −2.2 %−7.2 % range, 0.3–19.9
mg/kg PO SID
mean, 24.3;
range, 6.5–81.3
μg/ml
NA Neurological (hyperactivity) hyperactivity I
Gaskill and
Kimber 2010
PHB 30 80 % 65.7 %–94.3 % NA NA 12 m Neurological (ataxia, sedation,
hyperactivity, aggression), GI
(PP, anorexia, vomiting, diarrhoea),
Dermatological (skin problems),
ClinPath (increased ALP, ALT, lipase),
PU, PD
PP, PU, PD, vomiting,
skin problems,
hyperactivity
I
Aitken et al.
2003
PHB 95 40 % 30.1 %–49.8 % <2–> 10 mg/kg
PO SID
<65–> 120 μmol/l <3–> 12 m ClinPath (increased ALT, ALP, γ-GT,
GLDH, cholesterol, bile acids)
increased ALP,
ALT, GLDH
I
Dayrell-Hart
et al. 1991
PHB 18 NA NA median, 10.4;
range, 3.1–27
mg/kg PO SID
mean, 49.7;
range, 16–60
μg/ml (12 dogs
had >40)
median, 39;
range, 5–82 m
GI (hepatotoxicity)
(also all dogs were ataxic and
sedated)
NA I
Andrik et al.
2010
PHB 30
(15 epileptic
and 15
non-epileptic)
NA NA Epileptic dogs:
2 mg/kg PO BID
(increased if
necessary)
Non-epileptic
dogs: Initially at
2 mg/kg PO SID,
then increased at
8 mg/kg PO SID
NA Epileptic dogs:
range, 12–60 m
Non-epileptic
dogs: 5 m
GI (chronic hepatotoxicity), ClinPath
(increased ALP, ALT, AST, total
bilirubin, decreased albumin and
total protein)
increased ALT,
ALP
I
Litchfield et al.
1972
PHB 4 NA NA range, 5–40
mg/kg IV SID
NA 0.5 m ClinPath (increased ALP) NA I
Foster et al.
2000
PHB Experimental
dogs: 6
Epileptic
dogs: 10
70 % Experimental
dogs: 0 %
Epileptic dogs:
41.6 %–98.4 %
Experimental
dogs: mean,
6 mg/kg; range,
5.9–6.4 mg/kg
PO SID
Epileptic dogs:
range, 3.9–14.4
mg/kg PO SID
Experimental
dogs: mean,
63+/−15, range,
<65–194 μmol/L
Epileptic dogs:
mean, 110;
range, 72–171
μmol/L
Experimental
dogs: 3 m
Epileptic dogs:
range, 14–92 m
ClinPath (increased ALP, ALT, cholesterol) increased ALP I
Gaskil et al.
1999
PHB 78 40 % 28.8 %–50.6 % median 4; range,
1–16.4 mg/kg
PO SID
median, 17.6;
range, 4–70
μg/ml
median, 12.5;
range, 0.3–96
Endocrine (decreased total T4, free
T4, increased TSH)
Also, ClinPath abnormalities were
reported, i.e. increased ALT, ALP,
AST, γ-GT, fasting bile acids and
cholesterol, but no further details
are provided.
eythyroid sick
syndrome
I
Muller et al.
2000
PHB 12 91.6 % 100 % or
50.5 %–99.5 %
mean, 5; range,
4.8–6.6 mg/kg
PO BID
range,
20–40 μg/mL
7.1 m Endocrine (decreased total T4, free
T4, increased TSH, cholesterol and
total T3), Neurological (sedation for
the first 3 days)
No significant PHB’s effect on either
of the adrenal function tests
euthyroid sick
syndrome
I
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Table 1 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Muller et al.
2000
PHB 12 87.5 % 75.9 %–107.3 % mean, 5; range,
4.8–6.6 mg/kg
PO BID
range,
20–40 μg/ml
7.1 m ClinPath (increased ALP, ALT, γ-GT,
decreased albumin), Neurological
(sedation for the first 3 days)
increased ALP,
ALT, γ-GT
I
Kantrowitz
et al. 1999
PHB 55 NA NA NA median, 25.3;
range, 8.0–74.3
μg/ml
median, 7 m;
range, 1–120 m
Endocrine (decreased T4,
increased TSH)
eythyroid sick
syndrome
I
Chauvet et al.
1995
PHB 5 100 % 100 % NA range,
20–47 μg/ml
13 m Endocrine (increased ACTH, altered
ACTH stimulation and
dexamethasone supression test),
ClinPath (increased ALT, ALP,
decreased albumin, cholesterol),
PU, PD
increased ACTH,
altered ACTH
stimulation and
dexamethasone
supression test,
increased ALT, ALP,
decreased albumin,
cholesterol
I
Balazs et al.
1978
PHB 4 100 % 100 % 40 mg/kg
PO SID
NA 1.8 m ClinPath (increased ALP) increased ALP I
Conning and
Litchfield 1971
PHB NA NA NA NA NA NA ClinPath (increased ALP) increased ALP I
Sturtevant
et al. 1977
PHB 2 100 % 100 % 4.4 mg/kg PO TID NA 1 m ClinPath (Increased ALT, ALP) increased ALT
and ALP
I
Thrift et al.
2010
PHB 1 NA NA 6.4 mg/kg PO BID NA 2 m ClinPath (anemia, increased
ALT, ALP, AST)
idiosyncrasic anemia I & II
Kube et al.
2006
PHB 1 NA NA Initially 5 mg/kg
PO BID for 4 days,
then 3 mg/kg
PO BID
NA 2 m Dyskinesia (twitching episodes) NA II
Steiner et al.
2008
PHB 118 14.4 % 8.1 %–20.7 % NA Unclear NA ClinPath (Increased cPLI) NA II
Gaskill et al.
2000
PHB 88 9 % 3.0 %–15.0 % NA range,
39–130 mol/L
16 m GI (pancreatitis, increased amylase
and/or lipase activities)
increased amylase
and/or lipase activities
II
March et al.
2004
PHB 11 NA NA mean, 12.4+/−5.7;
range, 3.8–19.8
mg/kg PO SID
mean,
43.5+/−15.1;
range, 22.8–66
μg/ml
median, 6; range,
20.4–132 m
Dermatological (superficial
necrolytic dermatitis)
NA II
Weiss 2005 PHB 3 NA NA NA NA NA Blood dyscrasias (bone marrow
necrosis-myelofibrosis)
NA II
Jacobs et al.
1998
PHB 2 NA NA Case 1: 2.2 mg/kg
PO BID; Case 2:
4.4 mg/kg PO BID
NA Case 1: 5 m; Case 2: 3 m Blood dyscrasias (neutropenia,
thrombocytopenia), ClinPath
(increase ALP)
NA II
Weiss et al.
2002
PHB 1 NA NA NA NA NA Blood dyscrasias (myelofibrosis) NA II
Bevier et al.
2010
PHB 1 NA NA NA NA NA Dermatological
(superficial necrolytic dermatitis)
NA II
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Table 1 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Bersan et al.
2014
PHB 16 NA NA median, 3; mean,
2.75+/−0.43; range,
1.60–7.25 mg/kg
PO BID
median, 19;
mean, 22.4+/−5.5;
range, 13.2–30.5
μg/ml
median, 69.5;
mean,
72.1+/−sd 45.8;
range,
14–157 m
Blood dyscrasias (anemia and/or
thrombocytopenia and/or
neutropenia and/or pancytopenia)
anemia, pancytopenia II
Volk et al.
2008
(case series)
PHB
(monotherapy
prior to the
addition of
other AEDs)
8 NA NA NA but was within
normal reference
values
NA Approximately
2–3 m
Blood dyscrasias
(bone marrow suppression)
NA II
Habock and
Pakozdy 2012
PHB 37 22 % 16.8 %–57.2 % NA NA >1 m Blood dyscrasias (anemia and/or
thrombocytopenia and/or
neutropenia and/or pancytopenia)
NA II
Von Klopmann
et al. 2006
PHB 1 NA NA 2 mg/kg PO BID NA Blood dyscrasias (pancytopenia) NA II
Bizzeti et al.
2006
PHB 7 14.4 % −11.6 %−40.2 % NA NA NA Pancreatitis, ClinPath
(Increased amylase, lipase, cPLI)
NA II
Mathis et al.
2014
PHB 1 NA NA 2.1 mg/kg PO BID 27.5 μg/dL 6 m Blood dyscrasias
(bone marrow supression)
NA II
Daminet et al.
1999
PHB 9 0 % 0 % Initially 1.8–3 for
one week, then
2.7–4.5 mg/kg
PO BID
range, 65–150
pmol/L
0.8 m No adverse effects NA NA
Dyer et al.
1994
PHB 6 0 % 0 % 5 mg/kg PO BID range, 18–37
μg/ml
2 m No PHB’s effect on endogenous
ACTH and ACTH stimulation test
NA NA
Abbreviations: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz Chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily), TPM topiramate, w week(s),
y year(s)
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Table 2 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Studies AED No of dogs
treated
Prevalence 95 % CI
affected cases
Doses of AEDs Serum levels
of AEDs
Treatment
period
Body system affected and
adverse effects
Most common
adverse effects
Adverse
effect type
Rundfeldt et sl.
2015
Imepitoin 127
Imepitoin
high dose
group: 66
Imepitoin
low dose
group: 61
Imepitoin high dose
group: 86 %
Imepitoin low dose
group: 82 %
Imepitoin high
dose group:
77.6 %–94.3 %
Imepitoin low
dose group:
72.3 %–91.6 %
Imepitoin high
dose group:
30 mg/kg PO BID
Imepitoin low
dose group:
1 mg/kg PO BID
NA 1st phase: 3 m
2nd phase: 3 m
Neurological (hyperactivity,
disorientation), musculoskeletal
(unspecified), gastro-intestinal
(unspecified), respiratory
(unspecified), urogenital
(unspecified), other systems
(unspecified), general
(unspecified)
Disorientation,
hyperactivity
I
Tipold et al.
2014
Imepitoin 116 46.6 % 37.5 %–55.7 % 10–30 mg/kg
PO BID
NA 5 m Neurological (sedation,
hyperactivity), GI (PP, diarrhoea),
PU, PD, Renal/Urinary disorders,
ClinPath (increased creatinine)
PP, PD, PU, sedation,
hyperactivity
I
Tipold et al.
2014 (ELAS)
Imepitoin 32 NA NA 30, 90 or 150
mg/kg PO BID
(adverse effects
occurred mainly
in the higest
doses, i.e. 3X
and 5X the
recommended
dose)
NA 6 m Neurological (loss of righting
reflex, ataxia, intermittent
tremors, decreased activity,
nystagmus), GI (vomiting,
hypersalivation, white material
in the faeces), ClinPath
(increased creatinine),
Ophtalmological (lacrimation,
eye dryness, eye discharges,
relaxed nictitating membranes,
eyelid closure)
NA (infrequent
adverse effects)
I
Loscher et al.
2004, Rieck
et al. 2006
Imepitoin as
monotherapy
(12 dogs) and
imepitoin as an
adjunct to PHB
or Primidone
(17 dogs)
29 58.6 % 40.7 %–76.5 % Imepitoin: Initially
5 mg/kg PO BID
for 1 week, then
10–30 mg/kg
PO BID.
PHB: 6–23 mg/kg
PO SID.
Primidone:
25–53 mg/kg
PO SID
Imepitoin: mean,
4,000; range,
3400–7300 ng/ml
(2 h after dosing)
and mean, 650
ng/ml (12 h
after dosing).
PHB: range,
15–45 μg/ml
(2 dogs with
adverse effects
had 56.6–58.9
lg/mL).
Prim: NA
mean,
7.7 ± 0.7 m
Neurological (ataxia, sedation),
GI (PP), ClinPath (increased
ALT, ALP, GLDH)
PP I
Löscher et al.
2004 (ELAS)
Imepitoin 1st
experiment: 6
2nd
experiment: 6
0 % 0 % 1st experiment:
5 mg/kg PO BID
2nd experiment:
40 mg/kg PO BID
1st experiment:
range, 20–120
ng/ml
2nd experiment:
range,
4800–7400 ng/ml
1st experiment:
1.2 m
2nd experiment:
1.2 m
1st experiment: none
2nd experiment: none but
increase in body weight
NA I
EMA report
2012
(US field trial)
Imepitoin 110 NA NA range,
10–30 mg/kg
PO BID
NA NA Neurological (ataxia, hyperactivity,
anxiety, disorientation), ClinPath
(increased enzymes-unclear which)
tachypnoea, PD
ataxia, hyperactivity,
anxiety, PD, increased
liver enzymes
I
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Table 2 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
EMA report
2012
(unpublished
clinical trials:
Tipold 2006;
Heit 2011;
de Vries 2011)
Imepitoin NA NA NA 30 mg/kg PO BID
(Unclear if other
doses were
also used)
NA NA Neurological (ataxia, decreased
motor activity, disorientation,
hyperactivity, decreased sight,
increased sensitivity to sound),
GI (vomiting, diarrhoea,
polyphagia), Renal
(increase creatinine)
ataxia, decreased motor
activity, disorientation,
hyperactivity, decreased
sight, increased
sensitivity to sound,
vomiting, diarrhoea
I
EMA report
(GLP toxicity
study 1)
Imepitoin 32 0 % Doses of 0,
31.6 mg/kg: 0 %
Other doses:
NA
Doses of 0, 31.6,
100 and 316
mg/kg/day PO
NA 1 m Neurological (decreased motor
activity), GI (hypersalivation,
vomiting), ECG modifications
No adverse effects in the
recommended doses; adverse
effects occurred only in
the highest doses
NA I
EMA report
(GLP toxicity
study 2)
Imepitoin NA NA NA Doses of 0, 31.6,
82.5 and 215
mg/kg/day PO
NA 3.2 m (followed
by a 1.2 m
recovery period)
Only vomiting occurred in
the 0 and 31.6 mg/kg/day
doses; adverse effects occurred
only in the highest doses
NA I
Abbreviations: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr, potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily), TPM topiramate, w week(s),
y year(s)
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Table 3 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Studies AED No of dogs
treated
Prevalence 95 % CI affected
cases
Doses of AEDs Serum levels of
AEDs
Treatment period Body system affected and
adverse effects
Most common
adverse effects
Adverse
effect type
Boothe et al.
2012
PBr 23 78.5 % 61.7 %–95.3 % mean, 30.6; range,
26–35 mg/kg PO
BID
mean, 1.9 +/− 0.6;
range, 0.9–3.3
mg/ml
approximately 6 m Neurological (ataxia,
hyperactivity, sedation), GI
(vomiting, diarrhoea, PP),
PU, PD
sedation,
hyperactivity,
ataxia, PD, PU
I
Pearce 1990 PBr as an adjunct to PHB 10 40 % 9.6 %–70.4 % PBr: 22 mg/kg
PO SID (dose
increases occurred)
PHB: median, 3.3;
mean, 3.8 mg/kg
PO BID (dose was
reduced by a mean
of 50 % in 7/10
dogs during the
PBr treatment)
PBr: mean, 810;
range, 500–1625
mg/l
PHB: mean, 29.7;
range, 17–45
ug/ml
median, 7;
mean, 7.8 m
Neurological (ataxia,
sedation, hyperactivity),
PU, PD
ataxia, letargy,
PU, PD
I
March et al.
2002
PBr 6 20 % −12.0 %−52.0 % 30 mg⁄kg
PO BID
median, 245;
range, 178–269
mg/dL
3.9 m
(adverse effects
occurred after this
period when dose
adjustments
occurred (NA))
Neurological (ataxia,
paraparesis, hyperactivity)
ataxia,
paraparesis
I
Rossmeisl et al.
2009
PBr as an adjunct to PHB
and/or other AEDs
1298 2 % 1.2 %–2.8 % PBr: 44.9+/−1.7
mg/kg PO SID
PHB: 6.3+/−0.4
mg/kg PO SID
PBr: 3.7+/−0.3
mg/ml
PHB: 31.4+/−1.2
μg/dl
NA Neurological (sedation,
ataxia, paraparesis,
tetraparesis)
sedation,
ataxia,
paraparesis,
tetraparesis
I
Dayrell-Hart B et
al. 1996
PBr 238 10.9 % 6.9 %–14.9 % NA 21 affected dogs
had >2.3 mg/ml
and 5 affected
dogs had <0.5
mg/ml
NA Neurological (ataxia,
sedation)
ataxia,
sedation
I
Podell and
Fenner 1993
PBr as an adjunct to PHB
and/or other AEDs
23 78 % 61.1 %–94.9 % PBr: mean, 20.75;
range, 13–40
PO BID
PHB: NA
PBr: 161 mg/dl
PHB: 37.8 mcg/ml
mean, 15;
range, 4–33 m
Neurological (ataxia,
sedation), GI (PP), ClinPath
(increased serum chloride),
PU, PD
PU, PD, PP,
sedation
I
Chang et al.
2006
PBr
(monotherapy
or as an
adjunct to PHB)
Monotherapry: 4
Adjunctive
Therapy: 10
Monotherapry:
62.5 %
Adjunctive
Therapy: 95 %
Monotherapy:
15.0–110.0 %
Adjunctive therapy:
81 %–109 %
NA NA median, 18;
range, 3–72 m
Neurological (ataxia,
hyperactivity),
Dermatological (pruritus),
GI (PP),
The adjunctive therapy
group had also PU, PD
and vomiting/diarhoea
Ataxia,
hyperactivity,
pruritus, PP
I
Yohn et al. 1992 PBr as an
adjunct to PHB
1 NA NA NA 2.7 mg/ml 1 m Neurological (sedation,
ataxia, paraparesis,
anisocoria)
NA I
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Table 3 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Kantowitz et al.
1999
PBr
(monotherapy
or as an
adjunct to PHB)
Monotherapry: 15
Adjunctive
therapy: 8
NA NA NA Monotherapy:
median, 1985;
range, 500–3419
mg/dL
Adjunctive
therapy: PBr:
median, 1399;
range, 584–2438
mg/dL. PHB:
median, 22.4;
range, 10.9–40
μg/ml
Monotherapy: median,
14.5; range, 3–37 m
Adjunctive therapy:
PBr: median, 5; range,
3–72 m. PHB:
median, 22; range,
3–96 m
Monotherapy: Normal
Adjunctive therapy:
Endocrine (decreased
total T4, free T4)
NA I
Srivastava et al.
2013
PBr as an
adjunct to PHB
6 100 % 100 % PBr: 30 mg/kg
PO SID
PHB: Initially
2.5 mg/kg, then
5 mg/kg PO SID.
NA mean, 11.50+/− 1.23;
range, 8–15 m
(on PHB).
Then, PBr started and
3 m later a reduction
of 50 % in the dose of
PHB was performed.
After 6 m, PHB was
completely withdrawn.
Neurological (ataxia), GI
(hepatoxicity, anorexia, PP),
ClinPath (increased ALT,
ALP, AST, bile acids),
PU, PD
(polyphagia, PU, PD
appeared after 1–1.5
years of PBr therapy)
PU, PD, PP I
Shaw et al. 1996 PBr as an
adjunct to PHB
1 NA NA PBr: 20 mg/kg
PO SID
PHB: 3.75 mg/kg
PO BID
PBr: 1100 mg/l.
PHB: 20.4 μg/ml
Approximately 21 m After PBr initiation:
Neurological
(sedation, ataxia)
NA I
Paull et al. 2003 PBr 5 60 % 17.1 %–102.9 % Initially 100 mg/kg
PO BID for 2 days.
Then,
30 mg/kg PO SID
for 180 days.
range, 88–300
mg/dL (only one
dog was >300
mg/dl)
6 m Endocrine (Euthyroid sick
syndrome with decreased
TT4 and normal TSH)
Placebo group had the
same results
NA I
Stabile et al.
2014
PBr as an
adjunct to PHB
1 NA NA PBr: Initially,
400 mg/kg divided
in six daily doses
for four days. Then,
14 mg/kg PO BID
PHB: Initially,
2.7 mg/kg, then
5 mg/kg and finally
6.4 mg/kg PO BID.
PBr: 15.9 mg/ml;
PHB: 23.7 μg/ml
≥26 m Neurological (sedation,
ataxia, generalised
appendicular repetitive
myoclonus), ClinPath
(pseudohyperchlormia,
increased ALP)
NA I & II
Gaskill and
Kimber 2010
PBr 32 85.9 % 73.8 %–98.0 % NA NA 12 m Neurological (ataxia,
sedation, hyperactivity,
aggression), GI (PP,
anorexia, vomiting,
diarrhoea, pancreatitis),
Dermatological (skin
problems), ClinPath
(increased ALP, ALT,
amylase, lipase), PU, PD
vomiting,
sedation, PP,
PU, PD
I & II
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Table 3 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Volk et al. 2008 PBr as an
adjunct to PHB
(prior to
addition of
other AEDs)
14 100 % 100 % PBr and PHB: NA
but were within
normal reference
values
PBr: 1.7+/−0.4
mg/ml
PHB: 35.5+/−6.3
μg/ml
≥2–6 m Neurological (ataxia,
aggression), GI (PP,
vomiting, pancreatitis),
ClinPath (increased ALT,
ALP) PU, PD
increased ALT,
ALP, ataxia,
aggression
I & II
Gaskill et al.
2000
PBr as an
adjunct to PHB
Clinical trial: 6
Case series: 19
Clinical trial:
50 %
Case series:
37 %
Clinical trial:
10.0 %–90.0 %
Case series:
15.3 %–58.7 %
(pancreatitis);
47.5 %–89.3 %
(increased
enzymes only)
Clinical trial: NA
Case series: NA
Clinical trial: NA
Case series: PBr:
range, 12.5-37.5
mmol/L; PHB:
range, 54–190
imol/L
Clinical trial:
approximately 1 year
Case series: NA
GI (pancreatitis, increased
amylase and/or lipase
activities)
pancreatitis,
increased
amylase and/
or lipase
activities
II
Steinmetz et al.
2012
PBr as an
adjunct to PHB
1 NA NA 101.19 mg/kg
SID PO (added at
the beginning of
the 4th year)
PHB: 4.9 mg/kg
BID PO
PBr: 45 mmol/l
PHB:
168.52 μmol/l
48 m (adverse effect
occurred after the
48 m)
Neurological
(neuromyopathy with
generalised low
motor signs)
NA II
Mackay and
Mitchell 1998
PBr as an
adjunct to PHB
1 NA NA PBr: Initially
200 mg/kg PO BID
for 3 days, then
30 mg/kg PO SID
PHB: 5 mg/kg
PO BID.
PBr: NA.
PHB: 126 umol/L
3 d
(signs started 3 d after
the loading dose of
PBr was initiated)
ClinPath (artifactual
hyperchloraemia and
negative anion gap),
Neurological (pacing,
disorientation), GI
(vomiting)
The Neurological and GI
signs were attributed to
hypercloraemia
NA II
Boynosky and
Stokking 2014
PBr as an
adjunct to PHB
2 NA NA Initially 40 mg/kg
PO SID, then
60 mg/kg PO SID
(case 1) or 86 mg/
kg PO SID (case 2)
Case 1: 2.9
mg/mL; Case 2:
initially 0.8, then
3 mg/ml (after
7.5 months of
treatment)
12 m
[adverse effects
occured 3 (case 1) and
8 (case 2) m after the
dose increase]
Dermatological
(panicculitis) accompanied
by sedation and anorexia
NA II
Steiner et al.
2008
PBr
(monotherapy
or as an
adjunct to PHB)
Monotherapy: 98
Adjunctive
therapy: 121
14 % Monotherapy:
8.2 %–22.4 %
Adjunctive:
5.9 %–17.3 %
NA range, 0.5–4.2
mg/ml (majority
of dogs; range,
1–2 mg/ml)
NA ClinPath (increased cPLI) NA II
Bizzeti et al.
2006
PBr as an
adjunct to PHB
7 43 % 6.1 %–79.4 % NA NA NA Pancreatitis, ClinPath
(increased amylase,
lipase,cPLI)
NA II
Abbreviations: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz Chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily); TPM Topiramate; w week(s),
y year(s)
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Table 4 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Studies AED No of
Dogs
Prevalence 95 % CI
affected case
Doses of AEDs Serum levels of AEDs Treatment period Body system affected and
adverse effects
Most common
adverse effects
Adverse
effect type
Volk et al.
2008
LEV as an adjunct
to PHB and/or PBr
14 7.14 % −6.3 %−20.6 % LEV: 10 mg/kg for 2 m, 20 mg/kg
for further 2 m, 10–20 mg/kg
until 6 m and then 10–20 mg/kg
long-term PO TID
PHB and PBr: NA but were within
normal reference values
PHB: 35.5+/−6.3 μg/ml,
PBr:1.7+/−0.4 mg/ml,
(prior LEV initiation and
2 m after initiation).
≥2–6 m Neurological (sedation) sedation I
Volk et al.
2008
(case series)
LEV as an adjunct
to PHB and/or PBr
and/or gaba
and/or TPM
8 25 % −2.6 %–18.6 % LEV: 30–32 mg/kg PO TID TID
PHB and PBr: NA but were
within normal reference values
NA Approximately
2–3 m
Neurological (sedation) sedation I
Muñana
et al. 2012
LEV as an adjunct
to PHB and/or PBr
and/or gaba
and/or zonisamide
28 57 % 38.7 %–75.3 % LEV: median, 20.6; range,
17–23.1 PO TID
PHB: median, 7.2; range,
3.8–17.2 mg/kg PO SID.
PBr: median, 34.0; range,
13.6–84.2 mg/kg PO SID
LEV: range, <2-50.8
μg/mL.
PHB: mean, 28.13;
range, 15.77–36.40 μg/mL
PBr: mean, 186.20;
range, 71.18–390 mg/dL
9 m (during
the 5th m no
AED was
administered)
Neurological (ataxia,
hyperactivity), GI:
(anorexia, vomiting)
ataxia I
Steinberg
2004
LEV as an adjunct
to PHB and PBr
15 0 % 0 % LEV: range, 7.1–23.8 mg/kg
PO TID
PB and PBr: NA
PHB: mean,
32.1+/−14.4 μg/ml.
LEV: NA
PBr: 2.2+/−0.7 mg/dl
median, 38;
range,
13.8–95.5 m
No adverse effects
attributed to LEV
NA I
Packer
et al. 2015
LEV as an adjunct
to PHB and PBr
52 46 % 32.5 %–59.6 % Maintenance group: mean, 19.5;
range, 9–26 mg/kg PO TID.
Pulse group: Initial dose at 60
mg/kg followed by 20
mg/kg PO TID
NA Maintenance
group: mean,
1.4; range,
0.3–7.5 y
Pulse group:
mean, 0.8;
range, 0.3–3.4 y
Neurological (ataxia,
sedation, aggression,
hyperactivity), GI (PP,
vomiting, diarrhoea), PD
(Three times more often
in the pulse group)
ataxia, sedation I
Fredso
et al. 2015
LEV 6 84 % 53.8 %–113.2 % median, 31; mean, 30.4;
range, 27.6–51.5 PO TID
median, 114; mean, 93;
range, 18–137 μmol/L
2–12 m Neurological (ataxia,
sedation, hyperactivity,
disobedience, attention
seeking), GI (PP, anorexia,
vomiting), PU, PD
PP I
Moore
et al. 2010
LEV 6 16.6 % –13.2 %–46.4 % At day one, a single dose was
administered: mean, 21.7;
range, 20.8–22.7 mg/kg PO.
Then: range, 20.8–22.7 mg/kg
PO TID for 6 d
289.31+/−51.68 μg/mL 0.25 m GI (vomiting)
(only one episode at
the first d)
NA I
Abbreviaions: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz Chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily), TPM Topiramate, w week(s),
y year(s)
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Table 5 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Study AED No of
dogs
Prevalence 95 % CI
affected case
Doses of AEDs Serum levels
of AEDs
Treatment
period
Body system affected
and adverse effects
Most common
adverse effects
Adverse
effect type
von Klopmann
et al. 2007
Zonisamide as an
adjunct to PHB
and/or PBr
11 72.7 % 46.4 %–99.0 % Zonisamide: mean, 8.9; range,
5–11 mg/kg PO BID
PHB and PBr: NA but
continued unchanged or
reduced if appropriate
Zonisamide: median,
19.2; range, 15.2–38.
4 lg/ml.
PHB: median, 121;
range, 66–150 5 lmol/l.
PBr: median 1.2;
range, 0.7–1.7 g/l.
range,
4–17 m
Neurological (ataxia, sedation),
ClinPath (increased ALP, ALT
and GLDH)
ataxia, sedation,
increased ALP
I
Chung et al.
2012
Zonisamide 10 10 % −8.6 %–28.6 % median 9.5; mean 8.65;
range 2.5–12 mg/kg PO BID
range,
15.24–22.41 mg/mL
median, 12;
mean, 11.2 m
Neurological (sedation),
GI (vomiting, anorexia)
sedation, vomiting,
anorexia
I
Dewey et al.
2004
Zonisamide as an
adjunct to PHB
and/or PBr and/or
felbamate and/or
gaba and/or cloraz
12 50 % 21.7 %–78.3 % Zonisamide: mean, 8.9; range,
5–11 mg/kg PO BID.
Other AEDs: NA but in 9/12
dogs concurrent AEDs doses
were eliminated or reduced.
Zonisamide:
median, 23.5;
mean, 21.2 μg/mL.
mean, 8;
median, 9;
range, 2–18 m
Neurological (ataxia, sedation),
GI (vomiting), ClinPath (ALP)
ataxia,
increased ALP
I
Walker et al.
1988
Zonisamide 40 NA NA 10, 30 or 75 mg/kg PO SID range, 10–140 ug/ml 13 m Neurological (aggression) GI
(emaciation), ClinPath
(increased ALP, decreased
albumin)
aggression,
increased ALP,
decreased albumin
I
Boothe et al.
2008
Zonisamide 8 0 % 0 % 6.9 mg/kg IV SID or
10.3 mg⁄kg PO SID
range, 6–55 mcg⁄ml 2 m Endocrine (Decreased
total T4)
(However, total T4 was
only slightly decreased at
the study end)
NA I
Cook et al.
2011
Zonisamide 1 NA NA range, 7.9–8.4 mg/kg PO BID 38 μg/mL 18 m ClinPath (mixed acid
base disorder)
NA II
Miller et al.
2011
Zonisamide 1 NA NA 7.7 mg/kg PO BID NA 0.3 m GI (hepatoxicity) NA II
Abbreviations: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz Chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily), TPM Topiramate, w week(s),
y year(s)
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Table 6 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Studies AED No of
dogs treated
Prevalence 95 % CI
affected cases
Doses of AEDs Serum levels
of AEDs
Treatment period Body system affected and
adverse effects
Most common
adverse effects
Adverse
effect type
Schwartz-Porsche
et al. 1982
Prim 30 NA NA range, 13–100
mg/kg PO SID
range,
6–37 μg/ml
range
6–96 m
Neurological (sedation, hind limb
weakness), GI (PP), PU, PD,
ClinPath (ALP, SGPT)
sedation, PU, PD I
Schwartz-
Porsche et al.
1985
Prim 20 NA NA range,
17–107 mg/kg
PO SID
range,
0.5–58 μg/ml
mean, 14; range, 6.0–
35 m
Neurological (sedation, hind limb
weakness, ataxia), GI (PP), PD,
ClinPath (ALT, ALP, GLDH)
sedation, PU,
increased ALT, ALP
and GLDH
I
Farnbach et al.
1984
Prim 23 4.3 % −4.0 %–12.6 % range, 15.2–82
mg/kg PO SID
range,
4.8–70.7 μg/ml
NA Neurological (sedation, ataxia) sedation, ataxia I
Cunningham et al.
1983
Prim 15 NA NA 10.6–39.4
mg/kg PO TID
mean,
2.4 μg/ml
9 m Neurological (disorientation, ataxia,
hyperactivity, pacing), GI (PP), PU, PD
PU, PD, PP,
drowsiness, ataxia
I
Poffenbarger et al.
1985
Prim (monotherapy or
as an adjunct to PHB)
3 NA NA Varied NA 8–84 m GI (chronic hepatopathy/
toxicity-hepatic chirosis)
chronic
hepatopathy/toxicity
I
Bunch et al. 1987 Prim 1 NA NA 13 mg/kg PO BID NA 4 d Neurological (hyperactivity) NA I
Bunch et al. 1984 Prim 22 93 % 82.3 %–103.6 % Prim: 33+/−19
mg/kg PO SID
Other AEDs: NA
NA range, 6–120 m GI (chronic hepatopathy/toxicity),
ClinPath (increased ALP, ALT, AST,
γ-GT, bile acids)
chronic hepatoxicity,
increased ALP, ALT,
AST, bile acids
I
Bunch et al. 1982 Prim 2 NA NA Case 1: 750 mg
in total PO BID
Case 2: 250 mg
in total PO BID
NA 24 m GI (chronic hepatopathy/toxicity) chronic hepatoxicity I
EPAR (US field
trial)
Prim 110 NA NA NA NA NA Neurological (ataxia, hyperactivity,
anxiety, disorientation), ClinPath
(increased enzymes-unclear which)
tachypnoea, PD
ataxia, PD, increased
liver enzymes
I
Raw and Gaskell
1985
Prim 52 35 % 22.0 %–48.0 % NA NA 48 m Neurological (ataxia), GI (PP), PD ataxia, PD, PP
Meyer and
Noonan 1981
Prim 6 100 % 100 % 30–40 mg/kg
PO BID
NA 3 m ClinPath (increased ALP, ALT) increased ALT, ALP I
Sturtevant et al.
1977
Prim 2 100 % 100 % 17.6 mg/kg
POTID
NA 1 m ClinPath (anemia, increased ALP) increased ALP I & II
Jacobs et al. 1998 Prim 1 NA NA 25 mg/kg PO BID NA 2 m Blood dyscrasias (neutropenia,
anemia, thrombocytopenia),
ClinPath (decreased albumin,
increased ALP)
NA II
Henricks 1987 Prim 1 NA NA 62 mg in total
PO BID
NA 2 m Dermatitis NA II
Balazs et al. 1978 Prim 4 0 % 0 % 40–80 mg/kg
PO SID
NA 1.75 m No adverse effects NA NA
Bunch et al. 1985 Prim 6 0 % 0 % NA NA NA No adverse effects NA NA
Abbreviations: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz Chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily), TPM Topiramate, w week(s),
y year(s)
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Table 7 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects
Studies AED No of dogs Prevalence 95 % CI
affected cases
Doses of AEDs Serum levels
of AEDs
Treatment
period
Body system affected
and adverse effects
Most common adverse
effects
Adverse
effect type
Govendir et al.
2005
Gaba as an
adjunct to PHB
and/or PBr
17 76.5 % 56.3 %–96.6 % Gaba: median, 35; range, 32–40
mg/kg PO SID.
PHB: median, 8; range, 6–26
mg/kg PO SID.
PBr: median, 24; range, 14–56
mg/kg PO SID.
Gabapentin: NA
PHB and PBr:
within normal
reference values
4 m Neurological (sedation,
ataxia), GI (PP,
pancreatitis, chronic
hepatoxicity), ClinPath
(increased ALP,
triglycerides), PU, PD
ataxia, sedation I
Platt et al. 2006 Gaba as an
adjunct to
PHB and PBr
11 54.5 % 25.1 %–83.9 % mean, 10.9; range, 9.3–13.6
mg/kg PO TID
median, 6.8;
mean, 8.4;
range,
2.2–20.7 mg/l
3 m Neurological
(ataxia, sedation)
ataxia, sedation I
Dewey
et al. 2009
Pregabalin as
an adjunct to
PHB and PBr
11 91 % 74.1 %–107.9 % Pregabalin: 2 mg/kg PO TID. The
dose was increased by 1 mg/kg
PO TID each w until 3 or 4
mg/kg PO TID.
PHB and PBr: NA but were
within normal reference values
Pregabalin:
median, 7.3;
mean, 6.4;
range 2–11
μg/ml
PHB: median,
27.1; mean, 27.7;
range 19.8–40
μg/ml
PBr: median,
1,6; mean, 1.9;
range, 0.2–2.81
mg/ml
3 m Neurological (ataxia,
sedation), ClinPath
(increased ALP, ALT)
PU, PD, PP were also
recorded but were
associated to the
combination therapy
with PHB and PBr
ataxia, sedation I
Ruehlmann
et al. 2001
Felbamate as
an adjunct to
PHB
6 33.3 % −4.4 %–71.0 % Felbamate: median, 63 (initial
dose) and 77 (final dose); range,
62–220 mg/kg PO SID.
PHB: 3.75 mg/kg PO BID
(discontinued 2 m after
felbamate initiation)
median,
35; mean,
13–55 mg/l
median, 9 m Haematological
(leucopenia,
lymphopenia,
thrombocytopenia),
keratoconjunctivitis
sicca
leucopenia,
lymphopenia,
thrombocytopenia
I
McGee et al.
1998
Felbamate NA NA NA Sub-chronic group: 250, 500, and
1000 mg/kg PO SID
Chronic group: 100 and 300
mg/kg PO SID
range,
16.5–79 μg/ml
Sub-chronic
group: 3 m
chronic
group: 12 m
Sub-chronic group:
Neurological (ataxia,
sedation, tremors), GI
(vomiting, salivation),
ClinPath
(increased ALT)
Chronic group:
Neurological (ataxia,
limb rigidity, tremors),
GI (vomiting, salivation),
ClinPath (increased
ALT, ALP)
Sub-chronic group:
ataxia, sedation,
tremors, vomiting,
salivation,
increased ALT.
Chronic group:
ataxia, limb rigidity,
convulsions,
vomiting, salivation,
increased ALT, ALP.
I
Dayrell-
Hart et al.
1996
Felbamate as
an adjunct to
PHB and PBr
16 25 % 3.8 %–46.2 % NA NA NA GI (chronic
hepatotoxicity)
chronic hepatotoxicity I
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Table 7 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Bunch
et al. 1985
Phenytoin
(monotherapy
or as an
adjunct to
Prim)
Monotherapy:
8
Adjunctive
therapy: 8
Monotherapy:
0 %
Adjunctive
therapy: 37 %
Monotherapy:
0 %
Adjunct
therapy:
−1 %–16.7 %
NA NA NA Monotherapy: None
Adjunctive therapy: GI
(anorexia, emaciation),
ClinPath (increased
ALP, ALT, bilirubin,
bile acids, γ-GT,
decreased albumin)
These dogs were
eventually euthanised.
Monotherapy: NA
Adjunctive therapy:
anorexia, increased
ALP, ALT, bilirubin,
bile acids, γ-GT,
decreased albumin
I
Bunch et al.
1984
Phenytoin
(monotherapy
or as an
adjunct to
other AED(s))
Monotherapy:
7
Adjunctive
therapy: 19
NA ΝΑ Phenytoin: mean, 21+/− 11
mg/kg PO SID
Prim: mean, 33+/−19 mg/kg
PO SID.
Other AEDs: NA
NA range,
6–120 m
GI (chronic
hepatoxicity), ClinPath
(increased ALP, ALT,
AST, bile acids)
Chronic
hepatoxicity,
increased ALP, ALT,
AST, bile acids
I
Meyer and
Noonan 1981
Phenytoin 6 100 % 100 % 13–19 mg/kg PO TID NA 3 m ClinPath (increased
ALP, ALT)
increased ALP and
ALT
I
Sturtevant
et al. 1977
Phenytoin 2 100 % 100 % 22 mg/kg PO TID NA 1 m ClinPath (increased
ALP, ALT)
increased ALP and
ALT
I
Bunch et al.
1982
Phenytoin as
an adjunct
to Prim
3 NA NA Case 1: Prim: 250 mg PO
BID; Phenytoin: NA.
Case 2: Prim: 750 mg PO BID
Phenytoin: 100–233 mg PO TID
Case 3: Prim: NA PHB: 150 mg PO
SID Phenytoin: 750 mg PO SID
1000 mg PO SID
NA Case 1:
48 m.
Case 2:
30 m
Case 3:
36 m
GI (chronic
hepatoxicity)
chronic
hepatoxicity
I
Weiss et al.
2002
Phenytoin 1 NA NA NA NA NA Blood dyscrasias
(myelofibrosis)
NA II
Bunch et al.
1987
Phenytoin as
an adjunct to
PHB and/or
Prim
3 NA NA Case 1: Phenytoin: 5 mg/kg PO
BID, then increased up to 15 mg/
kg PO TID. PHB: 0.8 mg/kg PO BID,
then increased up to 13 mg/kg PO
BID
Case 2: Phenytoin: 7.5 mg/kg PO
BID, then increased up to 15 mg/
kg PO TID. PHB: 1.1 mg/kg PO BID,
then increased up to 4.5 mg/kg
PO TID. Prim: 18.5 mg/kg PO TID
Case 3: Phenytoin: 5 mg/kg PO
SID, then increased up to 21 mg/
kg PO BID. PHB: 3 mg/kg PO BID.
Prim: 13 mg/kg PO SID, then
increased up to 26 mg/kg
PO BID
Case 1: NA
Case 2: NA
Case 3: NA
Case 1:
27 months
Case 2:
15 months
Case 3:
8 months
GI (hepatotoxicity) NA II
Nash et al.
1977
Phenytoin 1 NA NA 100 mg in total NA 1 d Idiosyncrasic hepatitis NA II
Bunch
et al. 1990
Phenytoin 8 0 % 0 % 40 mg/kg PO TID NA 13.5 m No adverse effects NA NA
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Table 7 Details of number of dogs, 95 % CI affected cases, AED doses and serum levels, treatment period and adverse effects (Continued)
Nafe 1981 Valproate
(monotherapy
or as an
adjunct to PHB
and/or Prim
and/or phenytoin)
Monotherapy:
NA
Adjunctive
therapy: 57
Monotherapy:
NA
Adjunctive
therapy:
2 %
Monotherapy: NA
Adjunctive
therapy:
−1.7 %–5.1 %
Sodium Valproate: Monotherapy:
200 mg/kg. Adjunctive therapy:
range, 25–40 mg/kg PO SID.
PHB, Prim and Phenytoin: NA.
NA mean,
4.9; range,
1–8 m
Neurological (ataxia,
sedation),
dermatological
(alopecia), GI
(vomiting)
Sedation, alopecia I
Kiviranta
et al. 2013
TPM 10 NA NA TPM: Initially 2 mg/kg PO BID for
0.5 m, then 5 mg/kg PO BID for
2 m, and then 10 mg/kg PO BID
for 2 m and then 10 PO TID for
2 m.
PHB, PBr and LEV: NA but were
within normal reference values
NA 2–6 m Neurological
(sedation, ataxia),
ClinPath
(increased ALP, ALT),
weight lose
sedation, ataxia, increased
ALP, ALT
I
Abbreviations: AED(s) anti-epileptic drug(s), BID bis in die (twice daily), Chloraz Chlorazepate, CSF cerebrospinal fluid, CL confidence level, Gaba Gabapentin, IE idiopathic epilepsy, LEV Levetiracetam, mmonth(s), NA Not
Available, PHB phenobarbital, PD polydipsia, PU polyuria, PP polyphagia, PBr potassium bromide, Prim primidone, PO per os, SID semel in die (once daily), TID ter in die (three times daily), TPM Topiramate, w week(s),
y year(s)
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but no correlation could be found between serum levels
and safety profile. In one study, however [90], there was
a correlation between the administered dose and the
safety profile; dogs treated with a higher initial dose
(i.e. 60 mg/kg) experienced more adverse effects com-
pared to dogs started on lower doses (20 mg/kg)
(65 % (95 % CI: 43.6–86.5 %) vs. 34 % (95 % CI:
14.6–53.4 %), p = 0.03).
Zonisamide
There was an overall weak level of evidence provided for
the zonisamide safety profile either as monotherapy or
adjunctive therapy. Seven studies [30, 56, 57, 61, 68, 97, 99]
presented data about the safety profile of oral zonisamide
either as monotherapy (5 studies) [30, 61, 68, 97, 99] or as
an adjunct to other AEDs (2 studies) [56, 57], giving a
combined sample size of 83 dogs.
Five studies reported type I and type II adverse effects
(Table 5). From these, 3/5 (60 %) and 2/5 (40 %) studies
reported type I adverse effects for zonisamide monother-
apy and adjunctive therapy (mainly to phenobarbital
and/or potassium bromide) respectively. Specifically, in
all of the studies, adverse effects most commonly in-
cluded sedation, followed by ataxia, vomiting and de-
creased serum ALP activity. Less commonly, increased
serum ALT and GLDH activity, aggression, anorexia,
emaciation and decreased T4 and serum albumin were
reported. In adjunctive therapy studies, adverse effects
most commonly included sedation, ataxia and increased
serum ALP activity, followed by vomiting, increased
serum ALT and GLDH activity. In monotherapy studies
all the adverse effects occurred at the same frequency;
increased serum GLDH and ALT activity were not re-
ported (Fig. 8). Two studies reported type II adverse ef-
fects including idiosyncratic hepatotoxicity and mixed
acid–base disorder (Table 5).
Adequate data to allow calculations of the prevalence
of adverse effects was reported in 4/7 (57 %) studies
(Table 5). From these, only one showed >50 % preva-
lence of adverse effects for the specific period of treat-
ment they conducted. Based on the 95 % CI, the
majority of the population experienced at least one ad-
verse effect in 25 % of the studies (Table 5).
Adequate information about the treatment period was
reported in all of the studies (Table 5). From these, in 3/
6 (50 %) the treatment period was relatively short
(<6 months). Adequate information about the doses was
provided in all studies (Table 5). The zonisamide main-
tenance doses exceeded the recommended dose margins
in two studies. Adequate information about the zonisa-
mide serum levels was reported in 6/7 (86 %) studies
(Table 5), but no correlation could be found between
serum levels and the safety profile.
Primidone
There was an overall weak level of evidence provided for
the primidone safety profile either as monotherapy or
adjunctive therapy. Sixteen studies [28, 32, 35, 52, 64,
65, 76, 82, 89, 91, 92, 95, 103–105, 113] presented data
about the safety profile of primidone as an adjunct to
phenobarbital [104] and as a monotherapy agent
(remaining studies), giving a combined sample size of
298 dogs.
Twelve studies reported type I adverse effects includ-
ing gastro-intestinal and neurological signs as the most
common (Table 6). Specifically, adverse effects most
commonly included increased serum ALP activity, ataxia
and polydipsia followed by sedation, hyperactivity,
chronic clinical hepatopathy/toxicity, polyphagia, dis-
orientation and then increased serum ALT activity, hind
limb weakness and polyuria. Less commonly reported ef-
fects included anxiety, tachypnea and increased serum
AST, γ-GT, bile acids, SGPT and GLDH activity (Fig. 9).
In two studies [32, 76] no adverse effects attributed to
primidone were reported. Three studies reported type II
adverse effects (Table 6). Specifically, blood dyscrasias
(anemia, thrombocytopenia and/or neutropenia) and
dermatitis were reported.
Adequate data to allow calculations of the prevalence
of adverse effects was reported in 7/16 (44 %) of the
studies (Table 6). From these, 3/7 (43 %) showed >50 %
prevalence of adverse effects for the specific period of
treatment over which it was conducted. Based on the
95 % CI, the majority of the population experienced at
least one adverse effect in 3/7 (43 %) studies (Table 6).
Adequate information about the treatment period was
reported in 13/16 (81 %) (Table 6). From these, in 6/13
the treatment period was relatively short (<6 months).
Adequate information about the dose was provided in
14/16 (88 %) studies (Table 6). From these 11/14 (79 %)
and 3/14 (21 %) reported doses for type I and type II ad-
verse effects respectively. The primidone maintenance
doses were higher than the recommended dose margins
in type I and type II adverse effects in 5/11 (45 %) and
1/3 (33 %) studies, respectively. Adequate information
about the primidone (phenobarbital) serum levels was
reported in 5/16 (31 %) studies (Table 6). Of these, all
reported type I adverse effects. The phenobarbital serum
levels were higher than the recommended margins in
3/5 (60 %) studies.
Gabapentin
There was an overall weak level of evidence provided for
the gabapentin safety profile. Two studies [58, 59] pre-
sented data about the safety profile of oral gabapentin as
an adjunct to other AEDs, giving a combined sample
size of 28 dogs.
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Both studies reported only type I adverse effects,
including neurological signs as the most common
(Table 7). Specific adverse effects most commonly in-
cluded sedation and ataxia. Less commonly reported
adverse effects were polyphagia, pancreatitis, chronic
clinical hepatopathy/toxicity, polydipsia, polyuria and
increased ALP activity.
Both studies showed >50 % prevalence of adverse ef-
fects for the specific period of treatment during which
they were conducted (Table 7). Based on the 95 % CI,
the majority of the population experienced at least one
adverse effect in one study (Table 7). In both studies the
treatment period was relatively short (<6 months). The
gabapentin maintenance doses were high but within the
upper recommended dose margins in one study. Gaba-
pentin serum levels were not measured and, thus, no
analysis to detect associations between serum levels and
adverse effects was performed.
Pregabalin
There was an overall insufficient level of evidence provided
for the pregabalin safety profile. One study [55] presented
data about the safety profile of oral pregabalin as an adjunct
to phenobarbital and potassium bromide in 11 dogs.
The study reported only type I adverse effects includ-
ing neurological signs as the main ones (Table 7). Specif-
ically, sedation, ataxia and increased ALP activity and
ALT activity were reported.
The study showed 91 % prevalence of adverse effects
for the specific treatment period in which it was con-
ducted. Based on the 95 % CI, the majority of the popu-
lation experienced adverse effects (Table 7). The
treatment period was relatively short (<6 months). No
correlation was found between pregabalin dose/serum
levels and adverse effects.
Valproate
There was an overall weak level of evidence provided for
the valproate safety profile. One study [62] presented
data about the safety profile of sodium valproate in dif-
ferent groups either as a monotherapy or as an adjunct
to phenobarbital, primidone or a combination of pheno-
barbital and phenytoin in 57 dogs. The study reported
only type I adverse effects including neurological,
gastro-intestinal and dermatological ones (Table 7). Spe-
cifically, vomiting, sedation, ataxia and alopecia were
reported.
The study did not show >50 % prevalence of adverse
effects for the specific period of treatment during which
it was conducted. Based on the 95 % CI, the majority of
the population did not experience adverse effects
(Table 7). The treatment period was unclear. No correl-
ation was found between valproate dose and adverse ef-
fects. The serum levels were not measured.
Felbamate
There was an overall weak level of evidence provided for
the felbamate safety profile either as monotherapy or ad-
junctive therapy. Three studies [47, 70, 78] presented
data about the safety profile of felbamate as monother-
apy [47] or as an adjunct to phenobarbital in particular
and potassium bromide (remaining studies), giving a
combined sample size of 22 dogs.
All studies reported type I adverse effects including
gastro-intestinal and neurological signs as the most com-
mon (Table 7). Specifically, adverse effects most com-
monly included ataxia, tremors, vomiting, hypersalivation
and increased ALP activity. Less commonly, clinical
hepatopathy/toxicity, increased ALT activity, sedation,
limb rigidity, leucopenia, lymphopenia, thrombocytopenia
and keratoconjunctivitis sicca were reported (Fig. 10).
Two studies reported type II adverse effects (Table 7).
Specifically, blood dyscrasias (anemia, thrombocytopenia
and neutropenia) and dermatitis were reported.
Adequate data to allow calculations of the prevalence
of adverse effects was reported in 2/3 (67 %) of the stud-
ies (Table 7) and none showed >50 % prevalence of
adverse effects for the specific period of treatment
during which they were conducted. Based on the 95 %
CI, the majority of the population did not experience
adverse effects (Table 7).
Adequate information about the treatment period was
reported in 2/3 (67 %) (Table 7) and it was relatively
short in one study (<6 months). Adequate information
about the dose and serum levels was provided in 2/3
(67 %) studies (Table 7). In both of these the mainten-
ance doses were higher than the recommended dose
margins. No correlation was found between serum levels
and adverse effects.
Topiramate
There was an overall weak level of evidence provided
for the topiramate safety profile. One study [54] pre-
sented data about the safety profile of topiramate as
an adjunct to phenobarbital, potassium bromide and
levetiracetam in 10 dogs. The study reported type I
adverse effects, including neurological and gastro-
intestinal as the most common. Specific adverse
effects most commonly reported were ataxia, sed-
ation, weight loss and increased ALP and ALT
activity. However, these adverse effects could be
attributed in part to the co-administered AEDs such
as phenobarbital and/or potassium bromide. The
prevalence of adverse effects was approximately
50 %. The treatment period was relatively short
(<6 months). The maintenance dose was within
recommended dose margins (Table 7). Topiramate
serum levels were not measured.
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Phenytoin
There was an overall weak level of evidence provided for
the phenytoin safety profile either as monotherapy or
adjunctive therapy. Nine studies [32, 35, 52, 87, 89, 91,
92, 108] presented data about the safety profile of
phenytoin as monotherapy (7 studies) [32, 34, 35, 52, 87,
91, 108] as an adjunct to primidone in particular and/or
potassium bromide (4 studies) [32, 89, 91, 92], giving a
combined sample of 66 dogs.
Five studies reported type I adverse effects including
gastro-intestinal as the most common (Table 7). Specif-
ically, increased serum ALP, ALT, bile acids and chronic
clinical hepatopathy/toxicity were most commonly in-
cluded. Less commonly, increased serum AST, γ-GT,
bilirubin and bile acids activity, decreased albumin, an-
orexia and emaciation were reported (Fig. 11). In the
monotherapy group, no adverse effects occurred in two
studies [32, 34].
Three studies reported type II adverse effects (Table 7).
Specifically, idiosyncratic hepatotoxicity in particular
and blood dyscrasias (anemia, thrombocytopenia and/or
neutropenia) occurred. Blood dyscrasias (pancytopenia)
were reported by the monotherapy study [87].
Adequate data to allow calculations of the prevalence
of adverse effects was reported in 4/9 (44 %) of the stud-
ies and all but two did not show >50 % prevalence of ad-
verse effects for the specific period of treatment they
were conducted. Based on the 95 % CI, the majority of
the population experienced adverse effect in two studies
(Table 7).
Adequate information about the treatment period was
reported in 8/9 (89 %) (Table 7). From these, in 6/8
(75 %) the treatment period was relatively short
(<6 months). Adequate information about the dose and/
or serum levels was provided in 7/9 (77 %) (Table 7). No
correlation could be found between dose and adverse ef-
fects. Phenytoin serum levels were not measured.
B) Safety profile comparisons between AEDs or between
AEDs-placebo
Phenobarbital monotherapy vs placebo or untreated
control
Total safety information was available in five studies
[33, 36, 40, 43, 80]. Adequate information to calculate
OR was provided in all the studies. Studies compared
endocrinal factors and liver enzymes between phenobar-
bital and untreated or placebo-control groups. Four
adverse effects were reported. The common estimated OR
was 6.21 (95 % CI: 3.28–11.75), showing a statistically
significant association (P < 0.001), with reduced odds of
overall adverse effects in the untreated controls. Thus,
treated dogs were over 6 times as likely to experience an
adverse effect compared to controls. However, moderate
heterogeneity was shown between studies (chi2 = 6.62,
P = 0.09). The OR for abnormal total T4, TSH and
increased ALP and ALT activity showed a statistically
significant association, with reduced odds of these
adverse effects in the controls (Fig. 12).
Phenobarbital monotherapy vs potassium bromide
monotherapy
Total safety information was available in five studies [3,
23, 29, 39, 75]. Adequate information to calculate OR
was provided in all the studies. Twelve adverse effects
were reported. The common estimated OR was 0.80
(95 % CI: 0.31-2.04), showing a statistically non-
significant association (P = 0.64) between monotherapies.
Low heterogeneity was shown between studies (chi2 =
1.07, P = 0.59). The OR for increased serum ALP activity
showed a statistical trend in favour of potassium brom-
ide. The OR for pancreatitis, vomiting and increased
serum amylase and lipase activity showed a statistically
significant association, with reduced odds of these ad-
verse effects in the phenobarbital group (Fig. 13).
Phenobarbital monotherapy vs levetiracetam
monotherapy
Total safety information was available in one study [27].
Eleven main adverse effects were reported. The common
estimated OR was 2.5 (95 % CI: 0.16–38.6), showing a
statistically non-significant association (P = 0.51) be-
tween monotherapies. The OR for hypoactivity showed a
statistically significant association, with reduced odds of
this adverse effect in levetiracetam monotherapy
(Fig. 14). Although the number of affected dogs did not
significantly differ between the groups, the frequency of
adverse effects (per dog) was higher in the phenobarbital
group in this study.
Phenobarbital monotherapy vs imepitoin monotherapy
Total safety information was available in two studies
[25, 42]. Adequate information to estimate OR was
provided in one study [25] (Fig. 15). Four adverse effects
were reported. The common estimated OR was 0.65 (95 %
CI: 0.38–1.10), showing a statistically non-significant asso-
ciation (P = 0.11) between monotherapies. The OR for
polydipsia and polyuria showed a statistical trend in
favor of imepitoin. The OR for sedation and hyper-
activity showed a statistically significant association,
with reduced odds of these adverse effects in imepitoin
and phenobarbital, respectively.
The same study [25] reported that liver enzymes
(serum ALP, γ-GT, ALT and GLDH) were increased
significantly (P < 0.001) in the phenobarbital group,
along with a statistically significant (P < 0.05) association
for dose dependence; neither such increase nor dose
dependence trend was seen in the imepitoin group.
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The second study [42], although the OR could not be
estimated, reported sedation, ataxia, polydipsia and poly-
uria in phenobarbital group, whereas no adverse effects
were observed in the imepitoin group.
Imepitoin monotherapy vs imepitoin adjunctive therapy
Total safety information was available in two studies
[44, 48]. Imepitoin monotherapy was compared to
imepitoin adjunctive therapy to phenobarbital and/or po-
tassium bromide. Three adverse effects were reported.
The common estimated OR was 0.58 (95 % CI: 0.19–
1.75), showing a statistically non-significant association
(P = 0.34) between the two therapies. No heterogen-
eity was shown between studies (chi2 = 0.00, P = 1.00).
The OR for increased serum ALP activity showed a statis-
tically significant association, with reduced odds of this
adverse effect in imepitoin monotherapy (Fig. 16).
Imepitoin monotherapy vs pseudo-placebo
Total safety information was available in one study [26].
Imepitoin monotherapy (high dose) was compared to
imepitoin monotherapy (low dose; pseudo-placebo group).
The study grouped the adverse effects into broad categor-
ies (e.g. neurological, gastro-intestinal, etc.). The adverse
effects were reported on the grounds of these categories
but they were not specified. The common estimated OR
was 1.39 (95 % CI: 0.53–3.64), showing a statistically
non-significant association (P = 0.5) between mono-
therapy and pseudo-placebo. The OR for neurological
signs (ataxia and hyperactivity/restlessness) showed a
statistically significant association, with reduced odds
of this adverse effect in low-dose imepitoin mono-
therapy (Fig. 17).
The study reported that the findings from the
hematology and biochemistry evaluation were unre-
markable and remained within normal reference ranges.
There was only a very low tendency for serum creatinine
activity to increase in the high-dose imepitoin mono-
therapy compared to low-dose, but this change was also
within normal ranges.
Levetiracetam adjunctive therapy vs placebo
Total safety information was available in one study [24].
The study compared adverse effects between levetirace-
tam (as an adjunct to phenobarbital, potassium bromide,
gabapentin and/or zonisamide) and placebo-control (as
an adjunct to phenobarbital, potassium bromide, gaba-
pentin and/or zonisamide). Four adverse effects were re-
ported. The common estimated OR was 1.82 (95 % CI:
0.62–5.35), showing a statistically non-significant associ-
ation (P = 0.28) between treatment and placebo (Fig. 18).
However, according to the study [24], a significant
Fig. 12 Forest plot comparing phenobarbital vs placebo/control. Odd ratios (95 % CI) of specific and total adverse effects for phenobarbital and
control groups
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increase in the prevalence of any of the reported adverse
effects (P = 0.013) and ataxia in particular (p = 0.002)
was noted in dogs receiving levetiracetam compared to
baseline.
Further comparisons between AEDs were not possible
due to the lack of comparison studies and/or insufficient
report of power analysis and data to allow additional
statistical analysis.
Discussion
To the authors’ knowledge, this is the first systematic re-
view, including a meta-analytic approach, of AEDs’ ad-
verse effects in dogs. The authors followed the PRISMA
statement to report this systematic review [120]. The po-
tential for development of AEDs’ adverse effects in dogs
are well accepted. Our systematic review found, however,
that the strength of evidence as well as the prevalence
and occurrence of adverse effects were variable among
different AEDs and even among studies evaluating the
same AED.
Main categories of adverse effects are type I (pharma-
cology-related) and type II (idiosyncratic). While type I
effects are dose-dependent, occur predictably and are
usually caused by a known pharmacological property of
the drug, idiosyncratic reactions cannot be explained on
the grounds of the drug’s known mechanisms of action
and usually occur unpredictably and irrespective of dos-
age [121]. In our study, type II adverse effects occurred
mainly in dogs receiving doses within the recommended
margins; however, these adverse effects occurred at
any dose. Type II adverse effects occurred in primi-
done, phenobarbital, potassium bromide and zonisa-
mide. Idiosyncratic reactions were usually caused
either by immune-mediated hypersensitivity reactions
or by cytotoxic effects of the drug or one of its metabolites
[121]. Due to the liver’s central role in drug metabolism it
is one of the major sites where idiosyncratic drug
reactions manifest. Individual differences in rate of
formation and detoxification of reactive metabolites
may explain why only certain patients develop idio-
syncratic reactions [121]. These unpredictable adverse
reactions occur rarely and therefore frequently remain
undetected during clinical trials until approval and
marketing of drugs. Once a large number of patients
is exposed to new or more AEDs, these adverse
effects may increase in frequency [122].
This systematic review identified and evaluated ninety
studies, the vast majority of which were UCTs, retro-
spective case series, and reports derived from second
and third groups. In total, the data of 4102 dogs were in-
cluded. Direct and indirect comparisons among drugs
based on the frequency, proportion and prevalence of
adverse effects in each AED and study showed that leve-
tiracetam and secondary imepitoin might be amongst
Fig. 13 Forest plot comparing phenobarbital vs potassium bromide.
Odd ratios (95 % CI) of specific and total adverse effects for
phenobarbital and potassium bromide groups
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Fig. 14 Forest plot comparing phenobarbital vs levetiracetam. Odd ratios (95 % CI) of specific and total adverse effects for phenobarbital and
levetiracetam groups
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the safest AEDs, followed by phenobarbital and potas-
sium bromide; a strong level of evidence was identified
supporting their safety profile. The remaining AEDs
showed a variety of adverse effects, but there was weak
evidence to support their safety profile. Direct compari-
sons could be made only between specific AEDs based
on the results of comparison group studies. It was found
that imepitoin tended to have a better safety profile than
phenobarbital. Levetiracetam appeared to have a better
safety profile than phenobarbital, and phenobarbital ap-
peared to have a better safety profile than potassium
bromide. However, neither association was statistically
significant. The trend for phenobarbital to have a safer
profile than potassium bromide supports a former high-
quality study which showed that phenobarbital had a
better safety profile than potassium bromide [23]. It is
interesting that this association was not statistically dif-
ferent in our meta-analysis. It could be that our statis-
tical methods applied were too stringent or that data in
our study were more heterogenous, due to the data de-
riving from various studies, making it less likely in this
systematic review to detect a statistical difference.
Equally though, it is acknowledged there may be no
major underlying biological difference in adverse event
rates between these therapies.
Similar to a previous systematic review of AED efficacy
[13], the majority of the studies included in this review
did not offer high quality of evidence. Studies in the first
group, which were considered to offer lower overall risk
of bias, were too few compared to other groups (study
group 1st:2nd:3rd proportion was 1:4:3). In addition,
only 16 and 33 % of studies included well-characterised
groups of IE and healthy non-epileptic dogs respectively.
Only 13 % of studies included good study population
size. Many studies had only a very limited follow-up
time to assess efficacy and tolerability (<6 months).
Therefore, the results should always be interpreted with
caution.
In contrast to AEDs’ efficacy evaluation, case reports
do have an important role in forming a safety profile of
an individual AED. Specifically, type II or other rare ad-
verse events are unlikely to be recognized by standard
clinical trials [123]. Searching the whole range of publi-
cations and including NRCTs, UCTs, observational and
descriptive studies might avoid missing important infor-
mation about rare adverse effects and removes potential
biases that could occur in systematic reviews which use
stricter exclusion criteria and do not include studies
other than RCTs [124]. A number of reviews of human
drugs have found that case reports and spontaneous
reporting systems provide better information about ad-
verse effects than clinical trials do [115, 125]. Indeed, in
our review, we found that case reports provided valuable
specifics for several kinds of adverse effects not reported
in other study designs. Therefore, although small case
series and in particular case reports are considered to
Fig. 15 Forest plot comparing phenobarbital vs imepitoin. Odd ratios (95 % CI) of specific and total adverse effects for phenobarbital and
imepitoin groups
Charalambous et al. BMC Veterinary Research  (2016) 12:79 Page 36 of 44
provide overall low quality evidence for many measure-
ment outcomes (e.g. AEDs’ efficacy), they can reveal valu-
able information as far as the safety profile is concerned
and were included in the current systematic review.
Difficulties in describing adverse effects among studies
It has been suggested that reporting of AEDs’ adverse
events in clinical trials is poor and has not improved
over the years [126]. Searching for information about ad-
verse effects can be quite complicated [127–129]. Little
evidence exists on the most appropriate searching
methods, and a study has assessed different methods in
retrieving studies of adverse effects [4]. This study found
that a combination of different search methods is re-
quired to retrieve as many studies as possible. The same
study, however, has also concluded that the most
Fig. 16 Forest plot comparing imepitoin monotherapy vs imepitoin adjunctive therapy. Odd ratios (95 % CI) of specific and total adverse effects
for imepitoin monotherapy and adjunctive therapy groups
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effective search methods might not be possible until
there is better reporting and indexing of records con-
cerning the adverse effects. Another recent study has in-
dicated that database searching using adverse effects
terms can retrieve the majority of articles (around 92 %)
on drugs’ adverse effects [130]. Our review used all the
possible searching methods and combinations of these
methods and terms in order to retrieve all or the vast
Fig. 17 Forest plot comparing imepiton vs pseudo-placebo. Odd ratios (95 % CI) of specific and total adverse effects for imepitoin and
control groups
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majority of the available studies reporting or assessing
AEDs’ adverse effects.
The majority of the studies for many AEDs, apart from
phenobarbital, primidone, imepitoin and secondary po-
tassium bromide and zonisamide, evaluated the drugs
when administered in combination with other AEDs,
making it sometimes difficult to determine whether clin-
ical signs could always be attributed to AEDs’ adminis-
tration. Therefore, should these AEDs be used and
investigated more frequently as monotherapy, future
analyses (i.e. randomised controlled clinical trials) may
allow even clearer conclusions on the safety questions
raised in the present systematic review.
In newer standardized trials every sign that occurs
during the study will be recorded as an adverse effect
even if it is not always associated with the treatment. In
addition, newer trials tend to include toxicology studies
in which the doses that are administered are sometimes
beyond the recommended treatment doses. Therefore,
newer trials will report more adverse reactions than
others. As imepitoin is a newly developed antiepileptic
drug it is possible that the adverse effects have been
more adequately captured than for older AEDs and that
certain reported adverse effects might have been over-
reported or drug unrelated. Furthermore, a few in-
frequent adverse effects were recorded and mainly
occurred in doses higher than the recommended
therapeutic ones. The longer a drug is on the market,
the likelihood of reports of adverse effects increases.
This should be considered when evaluating older AEDs.
The prevalence is a good indicator for evaluating the
safety profile of an AED in a study. However, a few limi-
tations originating from the evaluated studies were
detected in this review. For instance, in three studies
[31, 33, 76], the prevalence was 0 %, but the duration
was quite short and only a very small population was
included. In another study [75], although a very large
population was included, the prevalence was 1 %,
possibly because the authors focused on reporting the
prevalence of pancreatitis only and the cases were
reviewed retrospectively. Similarly, in 23 studies [31, 34–
36, 38–40, 43, 45, 46, 49–52, 69, 76, 81, 83–85, 87, 93,
103], the authors focused on reporting only specific ad-
verse effects and, therefore, other adverse effects may
have been under- or misreported. In seven studies [36,
81, 83, 85, 87, 89, 104], prevalence was not calculated
because only dogs with adverse effects were included. In
16 studies [28, 30, 37, 39, 42, 47, 49, 54, 64, 65, 84, 85,
87, 91, 112, 113], the total number of affected dogs was
not very clear and therefore prevalence could not be
calculated (risk of prevalence data loses). Lastly, preva-
lence is difficult to derive from case reports.
There have been some characteristics in the included
studies that might have influenced AEDs’ safety profile
Fig. 18 Forest plot comparing levetiracetam vs placebo. Odd ratios (95 % CI) of specific and total adverse effects for levetiracetam and
control groups
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[1]. First of all, the dose range of a particular AED sig-
nificantly varied among studies. Another characteristic
could be the differences in AEDs’ titration. The safety of
some drugs can be influenced by the method and speed
of titration [1]. For instance, imepitoin allows quick ti-
tration and dose adjustments in dogs with poor response
to the drug. However, this was not followed in one study
[25] due to the comparison with phenobarbital which
demands slow titration. Therefore, this could have nega-
tively affected imepitoin’s safety profile. In addition, the
number or frequency of AEDs’ administration could in-
fluence safety profiles. Specifically for the AEDs with a
short half-life, the number of daily administrations might
affect the probability of the occurrence of adverse-effects
that correlate to fluctuations of blood levels. However, it
has been suggested that this characteristic is not as im-
portant as the titration speed [1].
The duration of the study should be sufficient to allow
the most frequent adverse effects to occur. In many
studies, the relatively small treatment period provided
limited time for some adverse effects to occur. Durations
of the studies were very heterogeneous and thus the
spectrum of the observed adverse effects might have
been affected by it. However, one human study [1],
which evaluated the AEDs’ central nervous system ad-
verse effects, found that most of them occurred soon
after the beginning of treatment or shortly after a dose
increase. In our review, adverse effects occurred
throughout the treatment duration of the studies.
As was found in the previous systematic review of
AEDs’ efficacy [13], several aspects may have also ad-
versely affected the assessment of the reviewed studies.
Similarly, the main aspects in the current systematic re-
view were the difference of baseline signalment cha-
racteristics, heterogeneity in treatment initiation and
protocols between studies, range of study publication
dates, publication bias, the several sources of biases
related to the studies, the lack of high quality evi-
dence studies (i.e. bRCTs and bRELAS), lack of stud-
ies designed with primary aim to investigate AEDs’
safety profile and enrolment of relatively small num-
bers of animals.
In our study, although the safety profile for each indi-
vidual AED could be reported and assessed, there were
factors that limit definite conclusions on safety profile
among AEDs. In a few of the human systematic reviews
and/or meta-analysis on AEDs’ safety profile, statistical
methods (e.g. comparisons of odds ratio based on study’s
evaluated AED and the control group, difference risk ra-
tio, etc.) were conducted for contrasting and combining
results from different groups and studies with the aim to
identify similar patterns and sources of disagreement
among study results or other interesting relationships
that may have come to light in the context of multiple
studies. In veterinary medicine, though, due to the small
number of comparison (i.e. control AED or placebo)
clinical trials or ELAS, lack of standardized descriptions
of adverse events, variation in methods for data collect-
ing, significant differences among study designs, several
potential sources of bias and the fact that objective
quantifiable measures and severity of most complaints
were not considered in reports, a rigorous statistical
method analysis cannot widely be used and, therefore, a
meta-analytic approach is very difficult or even impos-
sible. However, in our study, we were able to perform a
statistical analysis and meta-analytic exploration for
comparison groups within individual studies as well as
among a few studies retrieved, which allowed us to
evaluate and compare the safety profile between specific
AEDs. Only a few more reliable comparisons about the
safety profiles could be made, mainly, among phenobar-
bital, imepitoin and potassium bromide.
Implications for research
The report and assessment of the safety profile of indi-
vidual AEDs on systematic reviews is very important,
but it is the authors’ opinion that the assessment and
comparison of the safety profile among AEDs through a
meta-analytic approach could offer even more valuable
information and facilitate the clinician’s decision on
which AED to choose in respect to its safety profile. Al-
though the prevalence of adverse effects in each study
provides a general indicator of each AED’s safety profile
and allows limited and indirect comparisons between
AEDs, the statistical analysis of comparison group stud-
ies is the essential factor that allows direct and more
established comparisons. Therefore, further comparison
studies are widely needed in order to perform a larger
scale meta-analytic study that would offer stronger con-
clusions and valuable information on which AED can be
considered the most or least safe. Towards this goal fur-
ther conduction of high quality controlled studies
(bRCTs and bRELAS) for type I adverse effects and offi-
cial report of type II adverse effects are vital.
Last, but not least, a further problem that was detected
by the evaluation of the studies in this review was the
lack of detailed or clear information. This resulted in dif-
ficulties when performing statistics for AEDs’ safety pro-
file comparisons. Therefore, it is essential that future
studies include as much accurate information as possible
and that scientists have wide access to results of clinical
trials and experimental studies.
Implications for clinical practice
It was found that levetiracetam might be one of the saf-
est AEDs based on individual drug assessments, which
was also supported by a strong level of evidence. Al-
though phenobarbital is believed to be more commonly
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associated with a higher adverse effects rate compared
to other AEDs such as levetiracetam or imepitoin, it
could be argued that it has been longer on the market
and a greater number of studies have involved phenobar-
bital; therefore the number of adverse event reports is
likely to be higher. The current evidence based on this
systematic review and the previous one [13] shows that
there is good level of evidence supporting phenobarbital
as one of the most effective AED, but it might have a
lower safety profile than other AEDs (i.e. levetiracetam
and imepitoin). There was, however, no statistically sig-
nificant association between the overall safety profile of
phenobarbital and imepitoin or levetiracetam. Only for
sedation, hypoactivity and hyperactivity, a statistically
significant difference was detected in favour of imepi-
toin, levetiracetam and phenobarbital respectively.
Phenobarbital was not compared to further AEDs be-
cause of the lack of data (i.e. comparison studies). The
remaining AEDs showed a variable safety profile that,
potentially, could be high or low; no evidence neither
was identified to support any of these statements, nor to
compare their safety to other AEDs.
In general, most of the adverse effects reported in all
AEDs, apart from the idiosyncratic ones, were not usu-
ally life threatening and subsided once doses and serum
levels were reduced or following complete AED with-
drawal. It is important for clinicians to be able to evalu-
ate the benefits (i.e. the efficacy, cost and frequency of
administration, pharmacokinetic properties, need for
blood monitoring and lack of possible drug interactions)
and risks (i.e. the potential prevalence and severity of ad-
verse effects, long-term impact of adverse effects on pa-
tient and owner’s quality of life, drug interactions)
before initiating treatment with a specific AED.
Conclusion
This systematic review provides an evidence-based
evaluation of the data on the AEDs’ adverse effects most
common usage for canine IE. Case reports were included
to ensure that this review would capture idiosyncratic or
other rare adverse effects. Only very few studies were
designed in a randomised, controlled, and blinded man-
ner and many of the studies included only a small study
population with unclear inclusion or exclusion criteria
and short term follow-up. Direct comparisons suggested
that imepitoin and levetiracetam might have a better
safety profile than phenobarbital, whilst the latter might
have a better safety profile than potassium bromide.
None of the comparisons showed a statistically signifi-
cant difference. Further comparisons for all the AEDs
were not possible as a considerable amount of studies
did not report power calculations or clear and adequate
data to allow further statistical analysis. Individual AED
assessments showed that levetiracetam might be one of
the safest AEDs followed by imepitoin and then pheno-
barbital and potassium bromide; all supported by strong
level of evidence. The safety profile in other AEDs was
variable but insufficient level of evidence was found to
permit firm conclusions.
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